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Introduction 
INTRODUCTION 
Lectin was first discovered and partially isolated by Herman 
Stillmark, from castor bean in the year 1888, which he named as "ricin". 
He tested the effect of ricin on blood cells of different animals and 
observed agglutination of erythrocytes upon addition of ricin. The original 
observation of Stillmark on agglutination was further corroborated by 
others (Elfstrand, 1898; Michaelis and Steindoff, 1907; Kobent, 1913). 
Landsteiner and his co-workers discovered several agglutinins in the 
seeds of plants (Landsteiner et ai, 1907).Besides seeds, agglutinins 
were also found in the extracts of different parts of plants (Suga, 1910; 
Assmann, 1911; Schneider, 1912). 
Lectins were earlier called phytoagglutinins as they were mainly 
derived from plant sources. Later it was observed that lectins were not 
confined to plants only as originally believed, but were ubiquitous in 
nature, being found in animals, plants and microorganisms as well (Hirst, 
1941; Fisher, 1948; Lis and Sharon, 1986; Drickamer, 1988; Sharon and 
Lis, 1989; Leffler et ai, 1989). By the second half of 19th century the 
word "lectin" replaced the term phytohemagglutinin (Boyd and Shapleig, 
1954), however, the term phytohemagglutinin (PHA) is used for mitogenic 
lectins from kidney beans. 
According to Goldstein (1980), "lectin is a carbohydrate binding 
protein (or glycoprotein) of nonimmune origin which possesses the ability 
to agglutinate cells and/or precipitate glycoconjugates". More recently 
they have been defined as proteins that posses at least one non-catalytic 
domain that binds reversibly to specific mono or oligosaccharides 
(Peumans and VanDamme, 1995). 
Classification of Lectins 
A large number of plant and animal lectins have been 
characterized during the past decades. Plant lectins are classified on the 
basis of their specificity for the saccharide ligand (Kocoureck, 1986), 
while most animal lectins are classified on the basis of structural 
alignments and /or protein sequence homology, one is the family of 
widely distributed Ca^^-dependent lectins (Drickamer, 1988), and the other 
is the family of metal-independent p-galactoside binding lectins 
(Barondes, 1989; Rini, 1995). 
The mammalian lectins known so far have been classified mainly 
into five distinct families (Drickamer and Taylor, 1993; Gabius, 1997) as 
shown in Table 1, and detailed as follows: 
1. C-type lectins 
This is one of the best studied group of animal lectins. Lectins of 
this class require calcium ions for carbohydrate binding activity and are 
defined on the basis of their homology with the carbohydrate recognition 
domain (CRD) of the asialoglycoprotein receptor, and have rather low 
affinity to a monosaccharide (Drickamer, 1988). This family is very large 
and the number in mammals has already exceeded 50. 
Different members of this class exhibit distinct sugar binding 
specificities. Several of these lectins bind derivatives of mannose and N-
acetylglucosamine, although the relative affinities for sugars in this group 
may vary. Another set of C-type lectins bind Gal and GalNAc (Gal type 
ligands) with varying degrees of affinity. Among others, the family 
includes the endocytic glycoprotein receptor (Lodish, 1991), the selectins 
(Lasky, 1992; Bevilacqua, 1993), the maaophage mannose receptor and 
the soluble collectins (Drickamer and Taylor, 1993; Sastry and Ezekowitz, 
1993). 
Each C-type lectin is usually specialized for one or a limited 
number of phenomena and has a well defined function. Various functions 
have been attributed to these C-type lectins like involvement in 
catabolism of partially degraded glycoproteins containing terminal 
galactose or N-acetylgalactosamine residues (Schwartz, 1984; Breitffeld 
et a/., 1985), clearance of galactose terminal glycoproteins, desialylated 
erythrocytes and other blood cells (Sharon and Lis, 1989), cell-cell 
interaction during spermatogenesis and fertilization (Goluboff et a/., 1985), 
targeting of hydrolytic enzymes to lysosome (Sahagian, 198^t), regulation 
of blood clotting (Stokert, 1995; Dong et al., 1995) and as a protein that 
guides leukocytes (Crottet et al., 1996). These lectins are also linked to 
the chronic rejection process of transplanted tissues (Russel et al., 1994). 
These observations suggest that they possibly serve as contact points of 
recognition, adhesion and infiltration. 
Table -I 
Classification of animal lectins 
Family Structural 
Motif 
Calcium Carbohydrate 
dependence recognition 
1. C-type Conserved CRD Yes (most) Variable 
2. l-type Immunoglobin-
like CRD 
No Variable 
3. P-type Unique repeating variable Mannose-6-phosphate 
motif containing glycoproteins 
4. Pentraxins Pentamericsubunit Yes (most) Variable 
5. Galectins Conserved CRD No. 
(S-type) 
P-glactosides 
2. l-type 
l-type lectins belong to the immunoglobulin superfamily and are 
integral membrane proteins preferentially expressed on the plasma 
membrane of lymphocytes, neurons and endothelial cells (Stamenkovic 
and Seed, 1990; Wilson ef a/.,1991; Powell and Varki, 1995). It includes 
CD33, CD22 and MAG (myelin-associated glycoprotein) among others 
(Agrawal et al., 1990; Schultz et a/., 1992) CD22 is a cell surface 
phosphoglycoprotein detected on mature B cells. It appears to facilitate 
antigen-dependent B cell triggering by association with the B cell antigen 
receptor and cytoplasmic tyrosine kinases (Stamenkovic and Seed, 
1990). MAG is involved in the assembly of myelin sheath and may 
control the growth properties of neurons (Freeman et al., 1995). CD33 
is a marker of early myeloid cells and some monocyte populations 
(Tchilian et al., 1994). The other members of this family (sialoadhesin, 
neural cell-adhesion molecule, P^  glycoprotein, intracellular adhesion 
molecule and platelet/endothelial cell adhesion molecule) have different 
biological functions (Horstkorte et al., 1993; Fiblin and Tennekoon, 1993; 
DeLisser et al., 1993; McCourt et al., 1994; Crocker et al., 1995). 
3. P-type 
P-type lectins are mannose-6-phosphate recognising, calcium 
independent group of lectins which have unique repeating motif in the 
carbohydrate recognition region (Dahms, 1996). Besides, capturing 
secreted liposomal enzymes as mannose-6-phosphate receptor of 
macrophages/placental cells, P-type lectin is thought to position matrix 
proteoglycan degrading enzymes on the cell surface (Kornfeld, 1992). 
Moreover, P-type lectins have been found to be instrumental in detecting 
and purifying glycoconjugates with mannose-6-phosphate residues 
(Valenzano et al., 1993; Cummings, 1997). 
4. Pentraxins 
Lectins of this class appear unique in the property to precipitate 
the pneumococcal somatic C-polysaccharide by binding to its 
phosphocholine part. C- reactive protein (CRP) and serum amyloid P 
component (SAP) are members of pentraxin family (Kilpatric and 
Vo'anakis, 1991). The ligands for SAP, whose binding sides form a 
planar array, are quite abundant in microorganisms and can be the 
targets in the non-specific host defence by acute phase pentraxins. Like 
SAP, CRP has the capacity to bind Clq with the activation of classical 
complement pathway (Ballou and Kushner, 1992; Steel and Whitehead, 
1994). 
5. Galectins: A family of p-galactoside binding animal lectins 
Galectins, the large and growing class of p-galactoside binding 
proteins with related amino acid sequences and requiring no metal ions, 
have been found in tissues of invertebrates such as sponges, nematodes 
and vertebrates including mammals (Hirabayashi and Kasai, 1993; Oda 
et al., 1993). Most of the galectins can be solubilized in the absence of 
detergents therefore, are often referred as soluble tissue lectins. 
For the first time, Teichberg et al., (1975) had identified a p-
galactoside binding lectin in soluble extracts of electric organ tissue of 
an electric eel and purified it by affinity chrorriatography. 
Hemagglutination activity of this purified lectin, named electrolectin was 
inhibited by thiodigalactoside and lactose. Stimulated by the pioneering 
work on electrolectin, several groups began purifying related proteins 
from other vertebrate tissues. The first was galectin-1, purified from calf 
heart and lung by DeWaard et al. (1976). This was followed by the 
purification of the lectin from embryonic chick muscle (Den and 
Malinzak, 1977; Nowak et al., 1977). Like electrolectin, those from 
other sources were dimers with subunit molecular weights of about 
15 kDa. 
The evidences for other members of the galectin family came from 
the studies on extracts of chicken intestine where a lectin entirely 
different from the chicken muscle and liver lectins was demonstrated 
(Beyer et al., 1980). The lectin from intestine had a smaller subunit 
molecular weight (about 14kDa), behaved as monomer and had a 
somewhat different carbohydrate binding site. To distinguish these two p-
galactoside binding lectins from chicken, the one from muscle and liver 
was called chicken-lactose lectin-l or CLL-I, whereas, the lectin from 
intestine was called chicken-lactose lectin-ll on CLL-II (Hirabayashi and 
Kasai, 1993). 
The evidences of other members of this family came from the 
studies on mammals. Roff and Wang (1983) showed that cultured mouse 
and human fibroblasts had three p-galactoside binding proteins and 
purified one of these, now known as galectin-3. The three different P-
galactoside binding lectins purified from rat lung (Cerra et al., 1985), 
were galectin-1 ,-3 and -5. Later Leffler et al. (1989) found evidence for 
yet another rat lectin, now known as galectin-4, which was purified by 
affinity chromatography from extracts of rat intestine. Thereafter, work on 
the known galectins and the discovery of new ones was greatly 
facilitated by cloning and sequencing cDNA and genomic DNA (Ohyama 
et al., 1986). An attempt to make expression cloning of galectin-i cDNA 
from human hepatoma cDNA library (by screening with an antibody 
raised against galectin-1) led to the unexpected discovery of an 
additional cDNA that encoded galectin-2 (Gitt and Barondes, 1986). 
Availability of cDNAs for galectins provided large amount of 
recombinant proteins. These proteins were crystallized to determine 
structures in the presence of p-galactosides (Lobsanov et a/., 1993), 
which showed conserved amino acid sequence involvement in 
carbohydrate binding. The members of this family were classified 
according to their affinity for p-glactosides and significant sequence 
similarity in the carbohydrate recognition domain (Barondes et al., 
1994a). 
Structural Classification of Galectins 
Mammalian galectins are numbered sequentially, the number 
assigned to the individual galectins are the same as the accepted 
numbers for their genes in the Genome Data Base. The general 
designation of the genes encoding galectins is LGALS (Lectin, 
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galactoside binding, soluble) and gene numbering is being kept 
consistent with the numbering of the proteins, so that LGALS1 encodes 
galectin-1, etc. 
An increasing number of galectins have been found in various 
animal species, especially in mammals. So far the number of mammalian 
galectins have reached as many as 10, which are well characterized. 
The overall structure of galectins are represented schematically as shown 
in Fig.1. 
Galectin -1 
Galectin-1 is isolated as a homodimer of 14kDa and each subunit 
has a single carbohydrate binding site. The lectin is abundant in smooth 
and skeletal muscle and is also found in many other cell types (Gitt and 
Barondes, 1991; Poirier et a/., 1992; Barondes et a/., 1994b; Cannon et 
al., 1995; Baum et al., 1995). 
Galectin-2 
Galectin-2 behaves as a non-covalent dimer with subunits of about 
14 kDa. It has a much more restricted tissue disthbution compared to 
galectin-1, and is found only in gastrointestinal epithelial cells among a 
range of adult tissues (Gitt et al., 1992). 
Galectin-3 
Galectin-3 is isolated as a monomer of molecular weights ranging 
between 26 kDa to 30 kDa depending on the species (Herrmann et al., 1993). 
igure 1. Schematic representation of the overall structures of 
mammalian and some non-mammalian galectins 
The galectin carbohydrate-recognition domains (CRD) of 
about 130 amino acids are filled, and other domains are 
open or hatched. Some galectins have a CRD with only 
a few additional amino acids, other have two CRDs 
joined by a link peptide. Galectin-3 has one CRD joined 
to a different type of domain. 
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It consists of a short N-terminal domain, a proline and glycine rich 
domain of 9 amino acid repeats, and a C-terminal carbohydrate 
binding domain. It is abundant in activated macrophages, epithelial 
cells and is also found in other cell types (Cherayil et a/., 1989; 
Barondes et ai, 1994b). 
Galectin-4 
Galectin-4 was the first mammalian galectin reported with two 
carbohydrate recognition domains within one peptide chain {Oda et ai, 
1993). This galectin is a monomer with molecular weight of 36 kDa and 
is abundantly present in intestinal epithelium (Barondes et ai, 1994b). 
Gaiectin-S 
Galectin-5 was first discovered as a lactose binding protein 
isolated from rat lung (Cerra et ai, 1985) and erythrocytes (Whitney, 
1988). It consists of one CRD with little additional sequence, and has 
upto 40% identity with galectin-3 and -4. The deduced amino acid 
sequences of the cDNA predicted that galectin-5 is a monomeric protein 
of 16 kDa (Gitt et ai, 1995a). 
Galectin-6 
Galectin-6 has two CRDs that are about 80% identic<3l with those 
of galectin-4, but the link peptide joining them is 24 amino acids shorter 
than galectin-4 (Gitt ef ai, 1995b). Galectin-4 and -6 are so similar that 
they cannot be distinguished in most localization assays such as 
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immunohistochemical and northern blots, but their combined 
expression can be easily detected and distinguished from other 
proteins. Possibly galectin-6 is expressed in small intestine of 
several species (Gitt et al., 1997). 
Galectin-7 
Galectin-7 is a 14 kDa member of the lectin family present in all 
stratified epithelia. Its expression is independent of the stage of 
differentiation of the keratinocytes (Magnaldo and Darmon, 1997). It is 
found to be expressed in interfollicular epidermis and the outer root 
sheath of the hair follicle. Thus, galectin-7 is considered as a marker of 
all subtypes of keratinocytes and its expression does not seem to be 
influenced by the stages of differentiation (Magnaldo et al., 1995). 
Galectin-8 
Galectin-8, a protein of 35 kDa made up of tandem repeat CRDs 
joined by "link peptide" (Hadari et al., 1995), is structurally related to 
galectin-4 (34% identity), but unlike galectin-4, which is confined to the 
intestine and stomach, galectin-8 is expressed in liver, kidney, cardiac 
muscle, lung and brain (Hadari et al., 1995). Native galectin-8 exists as 
a monomer and its two CRDs are structurally different and interact with 
two different types of carbohydrates. Hence, galectin-8 is a naturally 
occurring, ubiquitous, bifunctional mammalian lectin (Hadari et a/., 1997). 
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Galectin-9 
Galectin-9 is a lactose binding protein reported to be expressed 
in a subpopulation of cells present in peripheral blood leukocytes and 
lymphoid tissues (Sahin et al., 1995). Mouse galectin-9 is found as part 
of an investigation looking for new galectins in embryonic kidney. It is 
also expressed in many tissues including kidney intestine and thymus 
(Wada et al., 1997). 
Galectin-10 
Galectin-10 has been isolated because of its unusual solubility 
properties. The Charcot-leyden crystal (CLC) protein was identified and 
isolated based on its unusual ability to spontaneously crystallize in 
inflammatory tissues. This protein which is extremely abundant in 
eosinophil leukocytes has a sequence and structure that closely 
resembles galectins. It has been shown to have weak lactose binding 
activity (Dyer and Rosenberg, 1996). 
Architectural Types of Galectin Family 
Based on protein architecture and its ability to function as a cross-
linker, the galectin family has been divided into three subgroups as 
shown in Fig.2 (Hirabayashi et al., 1992; Hirabayashi and Kasai, 1993). 
(i) Proto-type: usually forms a noncovalent homodimer, thus acting 
as a bifunctional cross-linker. Most of the investigated galectins, like 
electric eel lectin, two chicken isolectins, human placental lectin belong 
to this proto-type. New members of this type have also been reported in 
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Figure 2. Three architectural types of the galectin 
This classification is based on protein architectural features. 
Prototype can cross-link homologous carbohydrate ligands. 
Chimera type can cross-link two distinct ligands 
(Carbohydrate and non carbohydrate). Tandem-repeat-type 
galectins can cross-link two distinct carbohydrate ligands. 
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various animal species i.e. galectin-2,-5 and -7, frog galectin, nematode 
16 kDa gaiectins and two sponge isolectins (Gitt and Barondes, 1986; 
Pfeifer et al., 1993; Gitt et al., 1995a; Magnaldo et al., 1995; Ahmed et 
al., 1996b; Hirabayashi et al., 1996). 
ii) Chimera-type: consists of galectin and non-galectin domains, 
which may link carbohydrate and non-carbohydrate biomolecules. 
Chimera type (i.e. galectin-3) has been found predominantly in mammals 
but more recently it has been detected in the chicken too (Nurminskaya 
and Lindsenmayer, 1996). 
iii) Tandem-repeat-type: can cross-link different types of 
glycoconjuagates. The Tandem repeat-type galectin was recognised and 
reported for the first time in the nematode C.elegans (Hirabayashi et al., 
1992). Tandem repeat type gaiectins were not found earlier because of 
their basic insolubility This insolubility can be related to their potential as 
a hetero bifunctional cross linkers (Arata et al., 1997), involved in cell-
cell attachment as a possible junction protein. 
Biosynthesis and Secretion of Gaiectins 
The gaiectins are synthesized without transmembrane or secretion 
signal peptides, but usually have an acetylated N-terminus, and are 
initially found in the cytosol (Barondes, et al., 1994b). From the cytosol 
ga'ectins may be targeted for secretion by non-classical mechanisms 
possibly by direct translocation across the plasma membrane (Cooper, 
1997; Cleves et al., 1996). They may also be translocated into the 
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nucleus (Patterson, 1997), into vesicles (Dvorak et al., 1996), or accumulate at 
sub-cytosolic sites (Wasano and Hirakawa, 1995). Two galectins may be 
targeted to different sites within the same cell (Huflejt et al., 1997). 
Galectin-1 is synthesized on free cytoplasmic ribosomes and is 
dispersed in the cell cytosol (Wilson et al., 1989). The lectin also occurs 
in the extracellular space, where it coexists with laminin, one of the 
endogenous ligands of lectin (Cooper et a/.,1991). Pulse chase 
experiments demonstrated that the lectin is actively secreted from cells, 
rather than leaked from damaged cells (Lindstedt et al., 1993). 
During the study of galectin-1 biosynthesis in Chinese hamster 
ovary (CHO) cells, it was found that lectin is quantitatively secreted (Cho 
and Cummings, 1995b). To investigate whether glycoconjugate ligands of 
the lectin play any role in its secretion, the biosynthesis of lectin was 
investigated in a mutated CHO cell line. These cells were unable to 
synthesize galactose containing glycoconjugates due to a defect in their 
ability to transport UDP-Gal into the golgi lumen, because although the 
lectin was synthesized and secreted but it rapidly lost activity. The 
secreted lectin was termed as "metastable intermediate" which may be a 
folding intermediate of lectin. In normal cells it is hypothesized that the 
newly exported lectin associates with polylactosamine containing 
glycoconjugates to complete its folding and stability (Cho and Cummings, 
1997). Thus, these studies demonstrated that carbohydrate ligands help 
to stabilize the secreted lectin, but are not directly required for 
biosynthesis and secretion of the lectin. 
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Galectin-1 lacks a signal sequence required for its export by 
vesicle mediated exocytosis. The protein has to cross the plasma 
membrane for which two possibilities have been proposed. First, its 
secretion might involve a specific transmembrane transporter as in yeast 
cells (Cleves et al., 1996) and second, the cells might secrete galectin-1 
by a novel apocrine mechanism (Cooper and Barondes, 1990). 
Glycoconjugate Ligands and Intracellular Ligands for Galectins 
Glycoconjugate ligands. 
Even if p-galacotoside residues are components of almost every 
cell surface or extracellular glycoporteins, the carbohydrate binding 
specificities predict that galectins would bind only a subset of all the 
glycoproteins in a particular cell (Cooper, 1997; Chou and Cummings, 
1997; Akahani et al., 1997). The specificity studies also predict that two 
galectins should prefer a different set of ligands from the same cell but 
this has so far not been tested. The identified ligands (Cooper, 1997; 
Chou and Cummings, 1997; Pace and Baum, 1997; Akahani et al., 1997) 
include membrane-bound cell surface molecules such as cell signaling 
receptors (Frigeri et a/., 1993), soluble secreted molecules including 
laminin and mucins, and xenogenic molecules such as bacterial 
lipopolysaccharide (Mey et a/., 1996). 
Intracellular Ligands 
The galectins also have intracellular ligands and possibly have 
intracellular functions too. For example, galectin-3 interacts with RNA or 
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RNA binding proteins (Patterson, 1997), and a 67 kDa glucose binding 
lectin (Seve et al., 1993). The specific regulation (Sato and Hughes, 
1994) and targeting (Lindstedt et al., 1993) of its non-classical secretion 
also implies that the galectin interacts with intracellular ligands. 
As no intracellular p-galactosides have been identified, so the 
intracellular ligands must either interact with other sites on the galectin or 
with the lactose binding site by mimicking the shape of lactose. It is 
known that peptides may mimic galactosides and interact with galactose 
binding lectins and antibodies (Vaughan et al., 1996; Kooyman et 
a/., 1996). Moreover, the interaction of galectins with some intracellular 
ligands could be inhibited with lactose (Seve et al., 1993; Lindstedt et 
al., 1993; Yang et al., 1996) suggesting the involvement of the 
carbohydrate binding site. 
Physico-Chemical Properties of the Galectin Family 
Galectins are soluble proteins, having an affinity for 3 -
galactosides. Molecular weights of galectins from different sources are 
summarized in Table II (Paroutaud et al., 1987; Sakakura et al., 1990; 
Pfeifer et a/., 1993; Barondes et al., 1994b; Gitt et al., 1995a; Gitt et al., 
1995b; Sahin et al., 1995). The predominant form of galectins are dimers 
with subunit molecular weight of 14-17 kDa, whereas sponge galectins 
have been proposed to form trimers and/or tetramers (Pfeifer et al., 
1993). Most common and abundant galectin in mammalian tissue such 
as muscle, heart, lung, placenta, spleen, thymus, prostate and small 
intestine have subunit molecular weight very close to 14 kDa (Child and 
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Feizi, 1979 Hirabayashi and Kasai, 1984; Clerch et a/.. 1988; Gitt et 
al., 1992; Ahmed et al., 1996b). The hydrodynamic results show that rat 
lung galectin dimer exists as elongated ellipsoid under native conditions. 
Most of the galectins remain active only in the presence of reducing 
agents but few galectins are found to remain fully active for a long 
period of time if the intact proteins are stored in the presence of soluble 
or solid phase-bound ligand (Levi and Teichberg, 1981; Chou and 
Cummings, 1995a). 
Amino acid composition of galectins obtained from different 
sources of several mammals are found to be similar, if not identical 
(Birles et al., 1979; Crittenden et al., 1984; Cerra et al., 1985; Sparrow 
et al., 1987; Caron et al., 1987; Clerch et al., 1988). The total number 
of acidic amino acid residues are found to be significantly higher than 
the total number of basic amino acid residues. All galectins studied so 
far have blocked N-termini, and an acetyl group is demonstrated to be 
the blocking group (Hirabayashi e^  al., 1987). No galectins are found to 
be glycosylated. Galectins share characteristic carbohydrate binding 
domains of ~130 amino acids, v^ i^ich are highly conserved. All the known 
galectins lack a signal peptide, have cytoplasmic distribution, and are 
also secreted as soluble proteins by a non-classical secretory pathway 
(Hughes, 1999). 
Carbohydrate Binding Site and Specificity 
Galectins have in common a highly conserved carbohydrate 
binding site with affinity for lactose and N-acetyllactosamine (Lac Nac) 
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TABLE II 
Summary of the properties of galectin family 
Designations 
Mammals 
Gaiectin-1 
Galectin-2 
Galectin-3 
Galectin-4 
Galectin-5 
Galectin-6 
Galectin-7 
Galectin-8 
Galectin-9 
Galectin-10 
Birds 
Chick 14 K 
Chickie K 
Amphibians 
Xenopus16K 
Bufo 15 K 
Fish 
Electrolectin 
Congerin 
Nematodes 
Nematode32K 
Nematode16K 
Sponges 
GcLt 1/2 
funqi 
Gg1-l/ll 
Architectural Source 
Type 
proto 
proto 
chimera 
tandem 
repeat 
proto 
tandem 
repeat 
proto 
tandem 
repeat 
tandem 
repeat 
proto 
proto 
proto 
proto 
proto 
proto 
proto 
tandem 
repeat 
proto 
proto 
proto 
human,rat, 
mouse 
bovine 
human, mouse 
human, rat, 
mouse,dog 
human,rat. 
mouse 
rat 
mouse 
human, rat 
rat, human 
mouse, 
human 
human 
chick 
chick 
X. laevis 
B.arenarum 
electric eel 
conger eel 
C.elegans 
C.elegans 
G.cydonium 
C.cinereus 
Tissue/cell 
Distribution 
muscle, heart, 
lung, placenta 
brain, liver, thymus 
small intestine 
macrophage, colon, 
leukemia cells 
alimentary tract. 
epithelial cells 
erythrocytes 
gastrointestine 
skin 
liver, lung, 
kidney 
kidney 
thymus 
eosinophil, 
basophil 
skin, intestine 
muscle, liver 
skin 
oocyte 
electic organ 
skin mucus 
cuticle, 
pharynx 
? 
plasma 
membrane 
fruiting body 
M.W. 
(kDa]i 
14.5 
14.5 
29-35 
36 
17-18 
34 
14.5 
34 
35 
17 
14 
16 
16 
14.5 
16 
16 
32 
16 
13-18 
15.5/17 
Dominant 
ollgomeric 
Structure 
dimer 
dimer 
monomer 
monomer 
monomer 
? 
? 
monomer 
? 
dimer 
monomer 
dimer 
dimer 
dimer 
dimer 
dimer 
momoer 
dimer 
dimer 
dimer 
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(Lobsanov and Rini, 1997; Leffler and Barondes, 1986; Ahmed and 
Vasta, 1994), formed by part of the six-stranded p-sheet of the CRD p-
sandwich. The tightest interaction is with the galactose residue, but 
interaction with glucose is also significant, making the affinity for lactose 
50-150 fold higher compared to galactose for most galectins. However, 
the carbohydrate binding cleft formed by six-strand p-sheet extends 
beyond the lactose binding site and can accommodate an additional one 
to three saccharide residues. This may explain why 
polylactosaminoglycans are particularly good ligands for galectin-1 and 
galectin-3 (Chou and Cummings, 1997; Leffler and Barondes, 1986). The 
hydroxyls at C-4' and C-6' of galactose residue (in lactose) are very 
important for both variable and conserved CRDs, because neither 
epimerization (for OH at -4') nor substitutions (for both OH) are allowed 
without considerable changes in their affinity (Ahmed et al., 1996a). The 
oligosaccharide such as polylactosaminoglycans are typically bound by 
the galectins more tightly than lactose/N-acetyllactosamine. This increase 
in affinity suggests that in addition to the primary binding site, which 
accommodates, lactose/N-acetyllactosamine, there are secondary sites of 
interaction for more extended oligosaccharides (Rini, 1995). Secondary 
sites have been found to be important determinants of lectin binding 
specificity (Zhou and Cummings, 1993). The term subunit multivalency 
leads to increase in affinity and specificity for multivalent oligosaccharides 
and/or the ability to cross-link glycoconjugate containing substrate (Rini, 
1995). 
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Each galectin has a unique fine specificity, for example the affinity 
of galectin-1 for the blood group A tetrasaccharide is about 100 fold 
lower than that of galectin-3, and certain complex mucin derived 
saccharide, that bind galectin-3 well, do not bind galectin-1 at all 
(Sparrow et ai, 1987). Galectin-1, -3 and -5 also differ in their affinity 
for certain disaccharides such as Gal p i -3 GalNAc (Leffler and 
Barondes, 1986). The two chicken galectins, C14 and C16, were shown 
to differ in their fine specificity for a panel of synthetic lactose derivatives 
(Soils et al., 1996). 
Amino Acid Sequence and Homology 
Complementary DNA and amino acid sequence analysis have 
revealed that galectins lack typical secretion signal peptide and the N-
terminal amino acid residue is usually blocked by acetylation 
(Hirabayashi and Kasai, 1988; Barondes et al., 1994b). Comparison of 
amino acid sequence of galectin from various sources such as rat lung, 
human lung, hepatoma cells, placenta, porcine and calf heart, bovine 
brain, chicken embryonic skin and electric eel cells show extensive overall 
homology (Paroutaud et al., 1987; Wilson et al., 1989; Merkie et al., 1989 
Hirabayashi and Kasai, 1989; Gitt and Barondes, 1991). 
Galectins form an evolutionary related family with certain residues 
being conserved in all its members. The predicted secondary structure of 
galectins from different animals strongly suggest that these proteins have 
maintained structural homology during evolution and were derived from a 
common ancestral gene (Kasai and Hirabayashi, 1996). 
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The galectin-1 carbohydrate-binding domain (CRD) consists of 135 
amino acids tightly folded into a sandwich of a six stranded and five 
stranded 3-sheet (Lobsanov and Rini, 1997). Within the same peptide 
chain, some galectins have CRD with only a few additional amino acids, 
whereas others have two CRDs joined by a link peptide. The amino acid 
homology in the CRDs among different classes of galectins within one 
mammalian species ranges from about 20 to 40% (Oda et al., 1993). 
The identity of the same galectin from different mammalian species is 80 
to 90%, thus it is fairly easy to identify the equivalent lectin in different 
species. In contrast, it is more difficult to relate galectins from non-
mammalian species to those from mammals, for example two chicken 
galectins, C-16 and C-14, are 48% identical in sequence and each is 
about 56% identical to galectin-1 and 38% identical to galectin-2, 
therefore it is difficult to correlate these galectins on the basis of 
sequence (Barondes et al., 1994b). 
The amino acid sequence of CRD of galectin-1, having varying 
degree of identity with other mammalian and non-mammalian galectins is 
shown in Fig. 3, the critical amino acid residues involved in the 
saccharide binding are marked. 
Three Dimensional Structure 
By determining the structure of several galectins that had been 
crystallized in the presence of p-galactosides, the conserved amino acids 
that participate in the carbohydrate binding site were identified. 
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Figure 3. Comparison of amino acid sequence of various 
galectins 
For some galectins only partial sequences covering the 
carbohydrate binding domains are shown, as indicated by 
three dots precceding the sequece. percent identities to 
human galectin -1 are shown the right end. (*) denotes 
aitical amino acids residues involved in saccharide binding. 
Gaps have been introduced to maximize alignment of 
conserved residues. 
Ref: Gitt and Barondes, (1986); Hirabayashi and Kasai, 
(1988); Bladier ef a/., (1991); Hirabayashi, (1997). 
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The galectins are characterized by a conserved 14 kDa CRD with 
binding specificity for p-galactosides. Within the family the canonical 
CRD is found in a number of different structural organizations, such as 
the CRD alone (galectin-1, -2 and -7), the CRD linked to a ~ 15 kDa N-
terminal domain (galectin-3), the CRD linked to a short N-terminal 
segment (galectin-5) and to both N and C-terminal, CRD connected by a 
short polypeptide segment (galectin-4, -6 and -8) as shown in Fig. 1. 
Structural determination of a number of galectin subtypes and their 
carbohydrate complexes are currently in progress and considerable data 
derived from the dimeric galectin structure are already available 
(Lobsanov et al., 1993; Liao et al., 1994; Bourne et ai, 1994). 
The X-ray crystal structure of bovine galectin-1 (Liao et al., 1994) 
and human galectin-2 (Lobsanov et ai, 1993) have been determined in 
the presence of N-acetyllactosamine and lactose respectively. For dimeric 
bovine galectin-1, each monomer is composed of a five (F1-F5) and six 
(S1-S6) stranded anti-parallel p-sheet which are arranged in a p-
sandwich motif. The two monomers are related by a two fold rotation 
axis approximately perpendicular to the plane of the p-sheets. The SI 
and F1 p-strands of both monomers extend the characteristic anti-parallel 
hydrogen bond interactions aaoss the two fold symmetric dimer interface, 
resulting in a continuous 10 and 12-stranded antiparallel p-sheet. p-
strands are connected by relatively short loop regions and there are no 
a-helical segments found in the protein. The lactose/N-acetyllactosamine 
binding sites are located at opposite ends of the dimer and are defined 
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by clefts formed by p-strands S4-S6 on the 6-stranded p-sheet. The short 
loops and compact nature of the structure are consistent with the 
proteolytic stability of galectin-1 and the requirement for the entire 
polypeptide chain for carbohydrate binding activity (Abbott and Feizi, 
1991). The adjacent antiparallel p-strands, S3-S6 are made up of a 
continuous segment of polypeptide chain. All the amino residues of 
these p-strands are involved in direct interactions with the bound lactose/ 
N-acetyllactosamine moieties in galectin-1 and -2 (Lobsanov et a/., 1993). 
This region represents a carbohydrate binding cassette (Fig. 4) 
conserved by all members of the galectin family (Gitt et ai, 1992). 
The galactose moiety of the bound N-acetyllactosamine is found 
most deeply buried in the carbohydrate binding site. The highly 
conserved residues His-44, Asn-46 and Arg-48 make important hydrogen 
bond interactions with the galactose 04. The galactose 06 is involved in 
hydrogen bond interactions with Asn-61 and Glu-71. Trp-68 is found to 
make a stacking interaction with the galactose moiety (Rini, 1995). 
Neither the galactose 03 nor its 02 is directly hydrogen bonded to the 
protein. The carbohydrate binding site forms an open cleft at both ends 
suggesting that the galectins not only bind to repeating structures but are 
also able to bind an internal disaccharide unit (Lobsanov et ai, 1993). 
The importance of the role played by a number of the residues, involved 
in direct hydrogen bond interactions with the bound carbohydrate, has 
been confirmed by site directed mutagenesis studies (Abbott and Feizi, 
1991; Hirabayashi and Kasai, 1994). 
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Figure 4. The carbohydrate binding site of galectin-1 from bovine 
spleen. 
p-strands S3, S4, S5 and S6 correspond to the highly 
conserved carbohydrate-binding cassette containing all 
residues involved in direct interactions with N-
acetyllactosamine. 
NAG (A/-acetylglucosamine) 
GAL (galactose) 
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Functions of Galectins 
In the absence of a well defined function of galectins, several 
biological functions have been proposed. A number of observations have 
indicated their possible involvement in a variety of cellular processes 
such as embryogenesis, oncogenesis, communication, adhesion, 
transportation, guidance, modulation and signal transduction (Albrandt et 
al., 1987; Cooper et ai, 1991; Bao and Hughes, 1995; Kasai and 
Hirabayashi, 1996; Walzel et al., 1996; Ramkumar and Redder, 2000; 
Wada and Makino, 2001). These processes involve specific recognition 
of glycoconjugates by galectins. 
A possible role in cell adhesion was the early impetus leading to 
the discovery of galectins. Support for such a role came from localization 
of galectins at sites of adhesion as well as in vitro cell adhesion assays 
(Cooper et al., 1991; Chiu et al., 1994; Wasano and Hirakawa 1995). 
Galectin-1, -3 and -4, if coated on a surface, have been shown to 
promote adhesion of various cells by binding to cell surface 
glycoproteins. (Mahanthappa et ai, 1994; Huflejt et ai, 1997b), while 
galectin-1 and -3 were found to either inhibit (Cooper et ai, 1991; Sato 
and Hughes 1992) or promote adhesion (Zhou and Cummings 1993; 
Kuwabara and Liu, 1996) depending on conditions and cell type used. 
Different members of galectin family are expressed in a wide 
variety of cell types during embryogenesis {Poirier et ai, 1991). Galectins 
have been shown to mediate cell-cell and cell-matrix interactions and to 
influence cell growth (Sanford and Harris, 1990; Wells and Mallucci, 
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1991; Drickamer et al., 1993; Ramkumar and Podder, 2000). It also 
induces apoptosis of thymocytes and activated T-cells (Perillo et al., 
1995; Pace et al., 2000). For example, Galectin-1 can induce apoptosis 
in T-cell when added as an extracellular protein to the cells, the 
signaling is thought to involve CD45 and probably other membrane 
glycoproteins, and the T-cells have to be of the correct subset, or be 
primed into the correct stage to be responsive (Pace et al., 1999 Leffter 
Vespa et al., 1999). Galectin-3 has been proposed to protect cells 
against apoptosis, but when augmented intracellularly (Yang et al., 1996; 
Akahani et al., 1977). Recently, galectin-7 has also been found to be 
increased in apoptic cells (sunburn cells) in skin after ultra violet 
radiation (Bernerd et al., 1999). Galectins involvement in scavenging 
degraded cells by macrophages in lymphoid organs and in immune 
privileged sites suggest it may play a significant role in modulating the 
immune response (Riechert et al., 1994). 
Galectins also play important roles in inflammation process, as the 
administration of excess amount of recombinant proteins of galectin-1, -
3, and -9 inhibited proliferation and infiltration of macrophages into the 
glomeruli in anti-glomerular basement membrane nephritis in Wistar 
Kyoto rats (Tsuchiyama et al., 2000). Moreover, galectins are also 
involved in leukocyte chemotaxis and regulation of respiratory burst 
(Colnot et al., 1998). Moreover, In diabetic condition, galectin-3 is up-
regulated in mesengial cells, suggesting the possible involvement of 
galectins in the diabetic vascular complications (Pugliese et al., 2000). 
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Accumulating evidences suggest a possible involvement of 
galectins in malignant transfoimation and progression toward metastasis 
(Lee et al, 1991) For example the identification of galectin-1, -3 and -
8 in prostate carcinoma tumors suggests that these galectins might play 
a role in regulating metastatic spread of tumor cells (Hadan et a/, 1997 , 
Pacis et al, 2000, Brule et al, 2001, Tinari et al, 2001, Woo et al, 
2001, Rdrive et al, 2001) Moreover, a novel activity of nuclear galectin-
1 and -3 indicated that these galectins are required factors in the splicing 
for pre-mRNA (Patterson et a/, 1997, Tsay et al, 1999) Cross-linked 
galectm oligosaccharides have also been reported to be important 
information carrying molecules (Sharon and Lis, 1989, Lis and Sharon, 
1993, Kasai and Hirabayashi 1996) 
The galectins are found to be the mam components in linking 
individual aggregation factor to aggregation receptors at the plasma 
membrane and consequently bridging two cells together For example 
sponge galectm is one of the key molecules involved in both cell-cell 
and cell-matnx adhesion (Muller et al, 1997) In addition some members 
of galectm family are involved in host-pathogen interaction (Mandrell et al, 
1994, Mey et al, 1996) Recent studies have implicated that some galectins 
also have brfunctional activity as they have a cartxDhydrate binding site as well 
as catalytic site (Leonidas et al, 1995, Dyer and Rosenberg, 1996) 
The role of galectins in tissue organization especially in 
development and organization of kidney epithelium has been extensively 
studied (Hughes, 1997, Winyard et al, 1997, Bao and Hughes, 1999) 
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For example Cooper et al suggested roles of galectin-1 in maturation 
and organization of muscle fibers (Cooper and Barondes, 1990, Cooper 
et al, 1991, Gu et al, 1994) A role of galectin-3 in cartilage and bone 
formation/remodeling is suggested by its high expression (Colnot et al, 
1996, Aubin et al, 1995, 1996, Nurminskaya and Linsenmayer, 1996) 
Galectins have been isolated from brain (Bladier et al, 1989, Chadli et 
al, 1997, Zanetta, 1998), but they seem to be found in only a few 
restricted cell types in the central nervous system (CNS) in the CNS, 
galectin-1 has been found mainly in olfactory neurons, based on 
experiments in tissue culture it has been proposed that it acts in neuron 
fasciculation and guidance (Mahanthappa et al, 1994, Puche and Key, 
1995, Tenne-Brown et al, 1998) Galectin-3 is mainly associated with 
glia cells (Pesheva et al, 1998) and is induced m brain tumors 
(Bresalier et al, 1997) In peripheral nerve cells, galectin-1 and -3 were 
shown to have specific locations in dorsal root ganglia (Regan et al, 
1986) 
Biomedical uses of Galectins 
The study of galectins has been an area of active research in 
biomedical sciences as these molecules play important roles in a variety 
of biological processes (Lis and Sharon, 1986) Expenmental evidences 
support the possible use of galectins or galectin inhibitors in therapy as 
immunosuppressors in autoimmune disease (Offner et al, 1990), anti-
inflammatory agents, and anti-metastatic agents (LeMarer and Hughes, 
1996, Akahani et al, 1997) The well defined carbohydrate binding site 
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of galectins offers an attractive target for design of drugs inhibiting 
galectin function or ligands specifically targeting galectins If a galectin 
activity is limiting in a pathological condition but redundant under normal 
circumstances, then inhibition of this activity may be therapeutically 
valuable without causing severe side effects An indication that such 
drugs could be useful is that saccharides interacting with galectin-3 
inhibit metastasis of experimental rat prostate cancer in v/vo (Pienta et 
al, 1995) Detection of altered galectin expression in cancer cells 
(Konstantinov et al, 1996, Solis et al, 1996), inflammatory cells 
(Cherayil et al, 1989, Liv, 1993) or injured nerve cells (Cameron et al, 
1993) compared to normal cells may be of diagnostic value A labelled 
polysacchande, which acts as galectin-3 ligand (Mey et al, 1996) was 
found to specifically target inflammatory cells and melanoma cells when 
injected into animals (Diot et al, 1992, Mey et al, 1996) Thus galectins 
may also serve as an aid in the investigation and classification of 
lymphocytic proliferative diseases (Strubin, 1984) 
The discovery of anti-galectin antibodies in pathological sera also 
opens new diagnostic and potentially therapeutic avenues Antibodies 
against an 0 volvolus galectin were found in sera from patients with 
non-endemic loiasis, showing a hyperallergic reaction against the 
infecting filaria parasite, but not in sera from uninfected individuals or 
individuals with endemic loiasis not having hyperallergic reaction (Klion 
and Donelson, 1994) Antibodies against galectin-9 were found 
specifically in about 50% of sera from patients with Hodgkin's disease 
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but not in sera from healthy individuals or patients with other malignacies 
(Sahin et ai, 1995). Eventhough antibodies against galectin-3 have also 
been found in certain sera (Mathews et ai, 1995) but their biomedical 
significance remains obscure. 
As is evident from the review of literature, the galectins from 
different animals may differ significantly in structural and physico-chemical 
properties. The studies on brain galectins carried out so far are primarily 
confined to bovine, rat, mouse and human brains. The possible 
occurrence of the galectin in other mammalian brains, their structure and 
functional relationship are yet to be studied. Keeping this fact in mind the 
present study was undertaken to investigate the galectin from sheep 
brain. A detailed study of physicochemical properties and immunological 
cross-reactivity of the sheep brain galectin was undertaken. The purpose 
of this study was not only to look for lectins which display specific sugar 
specificity but to start a comprehensive study which will contribute to the 
pool of basic information necessary for the understanding of their 
biological functions. 
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T,7q)erimentaC 
MATERIALS 
Chemicals used for the studies were obtained from the sources 
given against their names. Glass distilled water was used in all the 
experiments. 
Chemical Source 
Acrylamide 
Agarose 
Ammonium persulphate 
Ammonium sulphate 
Bisacrylamide 
Sisco Res. Lab., India 
Sigma Chem. Co., USA 
Sisco Res. Lab., India 
Sisco Res. Lab. India 
Sisco Res. Lab., India 
Blue dextran Pharmacia Fine Chem., Sweden. 
Bovine serum albumin 
Bromophenol blue 
Chymotrypsin 
Cysteine 
Cytochrome c 
Divinyl sulfone 
Sisco Res Lab., India 
B.D.H. Poole, England 
Coomassie brilliant blue R-250 Sigma Chem. Co., USA 
Coomassie brilliant blue G-250 Sigma Chem. Co., USA 
Sisco Res. Lab., India 
Sisco Res. Lab., India 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
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Freund's adjuvant 
Hydrogen peroxide 
D-galactosamine 
Glycine 
Glutaraldehyde 
Galactose 
Difco Laboratories, USA 
Qualigens, India 
Sigma Chem. Co., USA 
Di-sodium hydrogenorthophosphate Qualigens, India 
Di-hydrogen sodiumorthophosphate Qualigens, India 
Sisco Res. Lab., India 
S.D. Fine Chemicals, India 
Loba Chemie, India 
Hemoglobin Sigma Chem. Co., USA 
Hydrogen peroxide and tetrabenzidine Genei, Pvt., Ltd, Bangalore 
lodoacetate 
lodoacetamide 
Lactose 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Sigma Chem. Co., USA 
Molecular weight Marker Proteins Genei, Pvt., Ltd., Bangalore 
Methyl p-D-Galactoside 
2-mercaptoethanol 
Sigma Chem. Co., USA 
Loba Chemie., India 
N,N'-dithio(bis)nitro benzoic acid Sisco Res. Lab., India 
N,N'-methylene bisacrylamide Sisco Res. Lab., India 
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Ovalbumin 
Sephadex G-100 
Sepharose 4B 
Sodium carbonate 
Sodium chloride 
Sodium dodecyl sulphate 
Soyabean trypsin inhibitor 
Sucrose 
Sigma Cham. Co., USA 
Pharmacia Fine Chem., Sweden 
Sisco Res. Lab., India 
Qualigens, India 
Qualigens, India 
Sigma Chem. Co., USA 
Sisco Res. Lab., India 
Sisco Res. Lab., India 
Tris (Hydroxymethyl) amino methane Qualigens, India 
Trypsin Sisco Res. Lab., India 
Sequencing grade reagents and solvents for protein sequencing, 
amino acid analysis and HPLC were from Applied Biosystems. The 
other chemicals and/or reagents used were of highest grade 
commercially available. 
Fresh sheep brains were routinely collected at the slaughter 
house (within 30 minutes after the animals were killed) in ice and 
processed for lectin purification within 2 hrs. of collection. Albino 
rabbits were used for collection of erythrocytes and raising of 
antibodies. 
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METHODS 
Determination of protein concentration. 
The protein concentration was determined by dye binding 
method (Bradford, 1976). as follows: 
(a) Preparation of dye solution 
One hundred milligram of coomassie brilliant blue G-250 was 
dissolved in 50 ml of absolute alcohol by shaking till all dye went 
into the solution. To this 100 ml of 85% orthophosphoric acid (v/v) 
was added and the volume was made upto 1 litre with distilled 
water. The dye was filtered through Whatman No. 1 paper before 
use. 
(b) Development of colour 
To 1ml of the protein solution 5 ml dye solution was added and 
the colour intensity was read at 595 nm within 5-10 min. against an 
appropriate blank prepared similarly without protein. Protein solution 
containing 30 to 300 jig of BSA was taken to obtain standard plot 
of protein. 
Carbohydrate estimation 
The procedure described by Dubois et al., (1956) was followed. 
Two ml of sugar solution containing 10 to 100 jig of carbohydrate 
was pipetted in test tubes and 0.5 ml of 80% phenol was added to 
it. This was followed by the addition of 5.0 ml concentrated sulphuric 
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acid, the stream of acid being directed against the liquid surface 
rather than the side of the test tube in order to obtain good mixing. 
The tubes were vortexed and placed for 20 min. at room 
temperature to cool. The colour was stable for several hours. The 
absorbance of the characteristic yellow orange colour was measured 
at 490 nm for quantitation of hexose content against blank prepared 
by substituting buffer for sugar solution. 
Determination of sulfhydryl groups. 
The method used was essentially that described by Ellman 
(1959). For the determination of exposed -SH groups, appropriate 
amount of protein was added in 100 mM Tris-EDTA buffer, pH 8.0 to 
give a total volume of 3.0 ml of the solution 0.1 ml DTNB solution 
(40 mg DTNB in 10 ml of 0.1 M Tris-HCI, pH 8.0) was added and 
the colour developed was read at 412 nm after 15 min. A reagent 
blank was used to account for the absorption of the reagent at 412 
nm. Cysteine was taken to obtain standard plot of SH groups. 
Thiol groups in \x moles were calculated using the standard plot 
of cysteine per \x mole of protein. 
Hemagglutination assay 
Hemagglutination activity was routinely assayed with rabbit 
erythrocytes by the methods of Lis et al., (1994). 
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(i) Preparation of erythrocyte suspension 
(a) Untreated erythrocytes 
Venous whole rabbit blood containing anticoagulant was diluted 
with an equal volume of 75 mM phosphate buffer saline (PBS) pH 
7.2, erythrocytes were collected by centrifugation at room temperature 
in a clinical table top centrifuge (2000 rpm for 5 min) and washed 
three to four times with PBS ( 5 ml per 1 ml packed cells). 
Washed erythrocytes were made 4% (3 x 10^ cells/ml) by adding 
PBS (4ml of cells per 100 ml PBS). 
(b) Enzymatically modified erythrocytes: (Trypsinized erythrocytes) 
An 8% (v/v) suspension of washed erythrocytes was prepared in 
PBS. Trypsin was added to a final concentration of 100 ng/mi (0.1 
ml of trypsin solution to 1 ml of erythrocyte suspension) and 
incubated for 1 hr. at 37°C. The trypsinized erythrocytes were 
washed four to five times with PBS and 4% (v/v) suspension was 
prepared for further use. 
(ii) Hemagglutination test 
A 50 |il of PBS was added to each row of wells on a miaotiter "V" 
plate, starting with the second well. To each of the first two wells 50 |il of 
the solution to be tested for activity was added and mixed by shaking the 
plate by hand. 50 jil of a liquid from the second well was transferred to 
the adjacent one, mixed and transferred 50 ^1 from the latter well to the 
next one and so on upto the last well. 
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This protocol produced two fold serial dilutions of the tested 
material i.e., 1:1, 1:2, 1:4, 1:6, 1:8 etc. 50 ^1 of the 4% (v/v) 
erythrocyte suspension was added to each well, mixed and left for 1 
hr. at room temperature. Highest dilution giving agglutination was 
noted. A mat of erythrocytes covering the well showed the 
occurrence of agglutination. In absence of agglutination, erythrocytes 
appeared as a button at the tip of the well. One agglutinating unit 
was arbitrarily defined as the minimal of material required to cause 
full agglutination under the above conditions. The titer of the tested 
solution was expressed as a reciprocal of the highest dilution 
showing agglutination. 
Brain cell agglutination / aggregation assay 
The brain cell agglutination activity was determined using 
dissociated cells from sheep, goat and buffalo brains without any 
chemical treatment. One gram tissue was isolated from the 
telencephalon of each brain and mechanically dissociated into 
separate cells by standardized method using a dissociation chamber 
containing a magnetic stirrer (Bologna et al., 1982, Caron et al., 
1987). Perfectly isolated cells were automatically and reproducibily 
obtained without adding any chemical substance. The cell suspension 
was fixed in 4% (v/v) glutaraldehyde in 75 mM PBS pH 7.2 
containing 75mM NaCI. After one hour, the cells were washed in 
PBS, rinsed twice in 0.2 M glycine, and dissociated again. Isolated 
cells were finally suspended at 6.25 x 10^ cells/ml of phosphate-
buffered saline pH 7.2 containing 75 mM NaCI.100 ^il of purified 
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galectin (10 |ig/ml) was added to tubes containing 100 n\ of a 
suspention of isolated fixed cells. After rotation at 70 rpm for 60 
min, small aliquots were carefully removed and the number of 
particles (i.e., single cells and clumps) per unit volume were 
determined using a Malassez hemocytometer. The rate of 
agglutination was expressed as the percentage decrease (A%) in 
particle number (Caron, et al., 1987). 
Determination of carbohydrate specificity by inhibition of 
hemagglutination 
(i) Qualitative determination 
Two millimolar solutions of the sugars to be tested were 
prepared. The titer of the lectin preparation was determined and 
diluted such that 50 |il had its titer 4. In wells of a microtiter plate, 
50 |il of the test carbohydrate solutions were mixed with 4 
agglutinating units of the galectin and kept for 5-10 min. and 50 \i\ 
of a 4% suspension of erythrocytes were added. The degree of 
agglutination was determined in different wells after 1 hr. Absence of 
agglutination indicated that the galectin was specific for the sugar in 
the well. 
(11) Quantitative determination 
Two fold serially diluted test sugar solutions were incubated for 
5-10 min at room temperature with 4 agglutinating units of galectin 
in microtiter plates. Agglutination was observed after 1 hr. of addition 
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of 50 |il of 4% erythrocyte suspension to each well. The highest 
dilution of the test sugar giving complete inhibit ion of 
hemagglutination was noted. 
Gei Filtration 
Sephadex G-100 column was prepared as recommended by 
Peterson and Sober (1962) at room temperature. The gel was 
allowed to swell in sufficient amount of distilled water for 6 hrs in a 
boiling water bath. The gel fines were removed by suspending the 
gel in two to four fold excess 75mM sodium phosphate buffer, pH 
7,2 and allowing 90-95% of the gel to settle down. The remaining 
gel in supernatant was rapidly removed by suction. A previously 
cleaned glass column mounted on a sturdy vertical support was filled 
to one third of its length with the operating buffer in order to check 
leaks and flush air bubbles from the dead space. The deaerated gel 
slurry was then gently poured with the help of a glass rod into the 
column with care to avoid generation of air bubbles. The column was 
left standing overnight. Flow rate was increased gradualy and after 
accomplishing a constant flow rate higher than that required for final 
elution the column was adjusted to the required flow rate. The 
packed column was thoroughly washed with two bed volumes of 
operating buffer (75 mM PBS, pH 7.2 containing 5 mM 2-
mercaptoethanol). In order to check uniform packing and to determine 
the void volume of the column, 0.2% (w/v) solution of blue dextran 
in operating buffer was passed through the column. The volume of 
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blue dextran or protein solution applied on the column was not more 
than 2-3% of the total bed volume. Three millilitre fractions were 
collected and assayed for protein. 
Molecular Weight Determination 
The molecular weight of the brain galectin was determined 
under native and denaturing conditions using gel filtration (a) and 
SDS -PAGE (b) respectively. 
(a) The molecular weight of the native and reduced sheep brain 
galectin was computed from its elution volume in Sephadex G-100 
column. The column was calibrated by determining the elution 
volumes of several globular proteins of known molecular weights 
like bovine serum albumin (66.2 kDa), ovalbumin (45 kDa), soyabean 
trypsin inhibitor (20.1 kDa) and cytochrome c (12.4 kDa). Affinity 
purified sheep brain galectin was applied to the column and 3 ml 
fractions were collected at a flow rate of 15 ml/hr. The data were 
analysed according to the theoretical treatment of Andrews (1964). 
The linear plot between VeA/o and Log M was used for calculating 
the molecular weight of the galectin. 
(b) The subunit molecular weight of sheep galectin was calculated 
by the procedure of Weber and Osborn (1969) using its mobility on 
SDS-PAGE. The mobilities of marker proteins determined under 
identical conditions were plotted against the logarithm of molecular 
weight. The analysis of data indicated a linear relationship between 
log M and relative mobility (Rm). The plot between log M and 
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relative mobility was used for calculating molecular weight of the 
galectin 
Determination of stokes radius 
The Stokes radius of sheep brain galectin was determined by 
the methods of Laurent and Killander (1964) using gel filtration data. 
The proteins bovine serum albumin (35.5A°), ovalbumin (27.SA"), 
Soyabean trypsin inhibitor (22 6A°) and cytochrome c (16.4 A°) were 
taken as standards 
The value of Kav of each marker protein was calculated from 
the formula Kav=\/e-VoA/t-Vo by substituting the values of Ve (elution 
volume), Vo (void volume) and Vt (total volume of column). 
A graph of the square root of the negative logarithm of Kav 
versus stokes radius gave a linear plot which was used for 
calculating stokes radius of the brain galectin. 
Slab Gel Electrophoresis 
A. Polyacrylamide gel electrophoresis 
Native PAGE was performed by the Tris-Glycine system of 
Laemmli (1970) using slab gel apparatus manufactured by Biotech, 
India Routinely 10% and 12.5% acrylamide gels were used. 
Concentrated stock solution of 30% acrylamide containing 0.8% bis-
acrylamide and 1.0 M Tris (pH 6 8 and 8.8) were prepared and 
mixed in appropriate amount to give the required final concentration. 
The solution was deaerated and poured in the mould formed 
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between the two glass plate (8 5 x 10cm) separated by 1 5 mm thick 
spacers Bubbles and leaks were avoided A comb providing a 
template for 7 wells was inserted into the gel before the 
polymerization began After polymerization the comb was removed 
and wells were overlaid with the running buffer Protein samples 
were prepared to give final concentration of 0 0625 M Tris HCI pH 
6 8, 10% glycerol and trace of bromophenol blue as a tracking dye 
Electrophoresis was performed in electrode buffer containing 0 025 M 
Tris, 0 2 M glycine, at 100 V till the tracking dye reached the 
bottom of the gel 
B. SDS polyacrylamide gel electrophoresis (SDS-F>AGE) 
SDS-PAGE was essentially performed by the method of Laemmli 
(1970) Stock solutions of 30% acrylamide containing 0 8% 
bisacrylamide, 1 0 M tris HCI (pH 6 8) and 10% of SDS were mixed in 
the specific proportion to give desired percentage of acrylamide Protein 
samples were prepared to give a final concentration of 1% SDS (w/v), 
0 5% 2-mercaptoethanol (v/v), 0 25 M Tris HCI, pH 6 8 and 10% 
glycerol (v/v) and a trace of bromophenol blue as a tracking dye 
Samples were then heated in a boiling water bath for about 3-5 mm , 
electrophoresis was carried out at lOOV for approximately 3 hr in 
electrode buffer containing 0 025 M Tns, 02 M glycine and 0 2% SDS 
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C. Coomassie blue Staining 
After electrophoresis the gels were stained with five gel volumes 
of 0.25% coomassie brilliant blue R-250 in 5% methanol and 10% 
acetic acid for at least 4 hrs. for destaining, the gels were incubated 
with shaking in 5% methanol and 7.5% acetic acid at room 
temperature. 
Sequencing of tryptic peptides, enzymatic digestion 
and peptide purification 
Sheep brain galectin (2mg in 3ml of PBS containing 5 mM 
mercaptoethanol and 0.5 M NaCI) was dialyzed against 0.01 M 
ammonium hydrocarbonate and then freeze-dried. The freeze-dried 
galectin was dissolved in 400 |il of 8 M deionized urea/0.05 M Tris-
HCI, pH 8.3, reduced with 0.045 M dithiothreitol (40^1) at 50°C for 
30 min, and then carboxamidomethylated with 0.1 M iodocetamide 
(80 ^1) under a nitrogen atmosphere at room temperature for 2 h. 
The carboxamidomethylated galectin was diluted to 2 ml with water 
and digested with trypsin/chymotrypsin (1:20 enzyme/substrate ratio) 
at 37°C for 20hrs. The tryptic peptides were separated by reverse 
phase HPLC (Pharmacia LKB) on a Vydoc CI8 column (4.6 x 250 
mm) equilibrated with 0.1% trifluoroacetic acid in water (v/v). Elution 
was performed at a flow rate of 0.8 ml/min with 0-60% acetonitrile 
linear gradient in 0.1% trifluoracetic acid (v/v) during 100 min. 
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Aminoacid sequencing and computerized sequence comparisons. 
The major perptides selected were applied to a polybrene-coated 
glass filter and sequenced in an applied Biosystems model 477A 
automatic sequencer (Applied Biosystems) run according to the 
manufacturer's instructions. Searches for the similarities to the 
determined sequence were performed with the aid of the Swiss port 
protein sequence data bank. The peptides were aligned by similarity. 
SPECTROSCOPY 
A. Ultra Violet Spectroscopy 
The UV spectrum of the native galectin in 75 mM PBS 
containing 5 mM 2-mercaptoethanol and oxidized galectin (by adding 
5 mM HjOj in absence of 2-mercaptoethanol) were measured on a 
Beckman U\/-640 spectrophotometer in the wavelength region 220-350 
nm. 
B. Fluorescence Spectroscopy 
The intrinsic fluorescence of the galectin was measured at 
25±0.2°C in Hitachi F 2000 spectrofluorimeter (Tokyo, Japan). The 
protein was excited {X ex) at 280 nm. Corrected emission spectra 
were recorded with excitation and emission band widths of 10 nm. 
Appropriate control containing substances used for the treatment were 
run and corrections made wherever necessary. 
The change in intrinsic fluorescence of native galectin in PBS 
(60|ig/ml) containing 5mM 2-mercaptoethanol and oxidised galectin (by 
47 
adding 5 mM H^Oj in absence of 2-mercaptoethanol), in presence as 
well as in absence of 0.1 M lactose, was followed by measuring the 
emission fluorescence in the wave length region 300-400 nm. 
C. Circular dichroism spectroscopy 
Circular dichroism spectra of native galectin and that after 
various treatments were measured in a Jasco J-810 
spectropolarimeter equipped with a temperature controlled sample cell 
holder. Spectra were recorded with scan speed of 100 nm/min and 
with a response time of 1 sec. and 1 nm band width. Each 
spectrum was the average of four scans. Measurements in the far 
UV (200-250 nm) as well as in the near UV (250-300 nm) regions 
were taken using the same concentration of galectin for each sample 
(250|ig/ml) appropriate control, containing the substances used for 
the treatment were taken. 
Modification of the brain galectin 
The rate of the reactions with 5 mM alkylating agents 
(iodoacetate, iodacetatmide. p-hydroxymercuribenzoate and N-
ethylmaleimide) in 75 mM PBS pH 7.2 containing 1mM 2-
mercaptoethanol and with oxidizing agent (5mM Hydrogen peroxide) 
in absence of 2-mercaptoethanol in the same buffer were determined 
at room temperature. After designated times, the modified brain 
galectin was titrated for hemagglutination assays. 
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Thermal stability 
The temperature stability of the galectin (125 iig/ml) was 
determined by incubating 100 |il sample in 75 mM PBS pH 7.2 
containing 5 mM 2-mercaptoethanol at various temperatures (30 to 
70°C) for 30 min, cooling it on wet ice and titrating with trypsinized 
rabbit red blood cells using microtiter plate assay 
pH stability 
To determine the optimal pH and stability of galectin activity, 
the purified galectin (125 iig/ml) in 50 |il of normal saline containing 
5 mM 2-mercaptoethanol were incubated with 50 l^l of following 
buffers, 0.1 M sodium acetate buffer (pH 3.5-5.5), 0.1 M sodium 
phosphate buffer (pH 6.5-7.5), 0.1 M Tris-HCI buffer (pH 8.5-9.5) and 
0.1 M g(ycine-NaOH buffer (pH 10.5-11.5) for 24 hrs at 4°C. The 
hemagglutination activity of the galectin was then titrated against 
trypsinized erythrocytes. 
Immunization 
Albino rabbits weighing between 1.5 to 2.0 Kg were used. Prior 
to immunization the rabbits were bled for obtaining serum that served 
as control in the studies. 300 |ig of antigen (galectin) in 0.5 ml, 
PBS pH 7.2 was mixed with 0.5 ml Freund's complete adjuvant to 
form a thorough emulsion. These preparations were injected at 
multiple subcutaneous sites on the back. After a rest of 15 days, a 
series of weekly booster doses of 150 ^g of galectin in incomplete 
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Freund's adjuvant were carried out. After the completion of five 
doses rabbits were bled, antisera collected and divided in small 
aliquots and stored at -20°C until further used. 
Ouchterlony double immunodiffusion 
The precipitation reaction in agarose gels was performed 
according to the method of Ouchterlony (1962) . One percent 
molten agarose in normal saline containing 0.1% sodium azide and 
30mM lactose (to prevent interaction of the lectin with the agarose or 
serum glycoproteins), was poured on clean petriplate and allowed to 
solidify at room temperature. Required number of weljs were cut from 
agarose and stored at 4°C. Antisera 10 to 40 ^1 and required 
amount of antigen were added in the central and peripheral wells 
respectively. The petriplate was incubated at 37°C for 4 hr. and then 
at 4°C overnight in order to get a clear precipitin band. The 
petriplate was photographed under proper illumination. 
Direct binding enzyme linked immuno-sorbent assay (ELISA) 
ELISA was performed essentially as described by Aotsuka ef 
a/., (1979). Polystyrene (96 wells) microtiter plates were coated with 
100 III of antigen at a concentration 2.5 ^g/ml in TBS (10 mM Tris, 
150 mM NaCI, pH 7.4) kept for 2hr. at room temperature and 
overnight at 4°C. The antigen coated wells were washed three times 
with TBS-T (20 mM Tris, 144 mM NaCI, 2.68 mM KCI, pH 7.4 with 
500 |il Tween) to remove unbound antigen. Unoccupied sites were 
blocked with 150 |xl of 1.5% BSA in TBS for 3 hr. at room 
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temperature. The plates were washed with TBS-T and serially diluted 
antiserum (100 lal/well) to be tested, were added to each well. After 
incubating plates for 2hrs. at room temperature, the bound antibodies 
were assayed by an appropriate anti rabbit goat IgG labelled with 
horse radish peroxidase using hydrogen peroxide and 
tetramethylbenzidine as a substrate. The plates were incubated for 1 
hr. and the absorbance was read at 450 nm. each sample was 
coated in duplicate. Results were expressed as a mean of A test- A 
control. 
Competition ELISA 
The antigentic specificity of the antibodies were determined by 
inhibition experiments (Hasan et al., 1991). Varying amount of 
inhibitors (0-20 |ig/ml) were mixed with a constant amount of 
antiserum (1:100 dilution). The mixture was incubated at room 
temperature for 2 hr. and overnight at 4°C. The immune complex 
formed was coated in the wells (instead of the serum). The 
remaining steps were the same as in direct binding ELISA. The 
results were expressed as percent inhibition. 
Percent inhibition = (1-A inhibited/A uninhibited) x 100 
A inhibited = absorbance at 450 nm in presence of varying amounts of 
inhibitors. 
A uninhibited = absorbance at 450 nm in the absence of inhibitors. 
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Dot blot analysis 
The specificity and the immunological cross reactivity of the sheep 
brain lectin antisera with other galactoside binding lectins present in liver, 
lung and heart was demonstrated by standard dot blot assay taking 
respective tissue homogenates. Two microliters of purified lectin sample 
was spotted on nitrocellulose paper and the blot was blocked by overnight 
incubation with 5% BSA solution. The blot was first incubated with rabbit 
anti-lectin sera (1:50 dilution) and then with peroxidase coated goat anti-
rabbit antibodies at the dilution of 1: 1000 for 2 hrs. at 37°C in a moist 
chamber. Extensive washings of the blot were carried out with 0.05%. 
Tween-PBS at every step to remove excess reagents. The binding of the 
sheep brain lectin and of the tissue lectins with anti sheep brain lectin 
antibodies were visualized by developing the blot with a mixture of 0.1% 
HjOj containing 1 mg/ml diaminobenzidine. 
Preparation of lactosyl-Sepharose Column 
The procedure of Porath and Ersson (1973) was adopted. Hundred 
ml of sedimented Sepharose 4 B beads were suspended in 100 ml 0.5 M 
Na^COj and washed several times until pHII .0 was obtained. The drained 
gel was collected and resuspended in 100 ml of 0.5 M Na2C03 to this 10 ml 
of divinyl sulfone was slowly added. The mixture was stirred gently for 70 
minutes at 23°C, filtered on Buchner funnel and washed several times with 
0.5 M Na2C03. The drained gel was further suspended in 100 ml of a 10% 
lactose (w/v) solution in 0.5 M Na^COg. The reaction was allowed to proceed 
for 15 hr. in cold with gentle stirring. The mixture was then filtered and 
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washed with 0.5 M Na^ COg in water and finally with 75 mM PBS pH 7.2. The 
column was stored in PBS containing 0.02% sodium azide at 4*'C. The 
column thus prepared can be reused indefinitely if washed with at least 5 
column volumes of PBS containing sodium azide after galectin had been 
eluted. Column was generally repacked after 5 uses. 
Isolation of galectin from sheep brain 
(i) Brain homogenization 
The freshly preleved brains were rinsed in saline solution. The 
meningeal membranes were carefully removed. Total brain was cut into 
small pieces and suspended in ice cold buffer A (75 mM Sodium phosphate, 
pH 7.2, containing 0.15 M NaCI, 5 mM 2-mercaptoethanol, 30 mM lactose, 
0.02% sodium azide and 10 mM EDTA) 1 gm of brain tissue/2 ml. 
Homogenization was carried out at 4°C in a stainless steel vessel using 
mixer table homogenizer at full speed for three periods of 1 min. with 1 
min. intervals. The homogenate was centrifuged in a Beckman J2-21 cooling 
centrifuge (JA-20 rotor, 10000 rpm for 30 min.) at 4°C. The supernatant 
(SI) was collected. 
(2) Fractionation of brain homogenate 
The supernatant of homogenate (SI) was centrifuged at 40,000 rpm 
for 1 hr. in Beckman L8-60 M ultracentrifuge using 60 Ti rotor. The 
supernatant (S2) was collected and kept on ice. To this soluble protein 
solution an equivalent weight of solid ammonium sulphate was slowly added 
to obtain a final 30% ammonium sulphate saturation and kept at 4°C for 10-
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12 hr. The precipitated proteins were removed by centrifugation at 5000 
rpm for 30 min. in a cooling centrifuge and the supernatant brought to 70% 
saturation with solid ammonium sulphate. After agitation for 6 hr. at 4°C, 
the precipitate was collected and dissolved (1/5th of the initial extraction 
buffer volume) in buffer B (75 mM sodium phosphate, pH 1.2, containing 5 
mM 2-mercaptoethanol, 0.15 M NaCI and 0.02% sodium azide). After 
extensive dialysis against buffer B, some precipitated material was removed 
by centrifugation at 40,000 rpm for 30 min. to obtain clear supernatant. 
The clear supernatant (S3) was finally applied to the affinity column. 
(3) Affinity chromatography of galectin 
The clear supernatant (S3) obtained was applied at room temperature 
to the chromatographic column containing 5 ml of gel extensively washed 
and equilibrated with buffer B. The unbound material was eliminated by 
washing with buffer B, until no protein was detected in the effluent. The 
specifically bound material was then eluted at 4°C with 0.2 M lactose in 
buffer B at a flow rate of 12 ml/hr. The protein content of 2 ml fractions were 
collected and assayed for protein estimation according to Bradford's method. 
The affinity purified galectin was dialyzed against 75 mM sodium phosphate 
buffer pH 7.2 containing 0.15 M NaCI, 5 mM 2- mercaptoethanol and 0.02% 
sodium azide to remove lactose. The hemagglutination activity of the 
dialysed galectin was determined with trypsinized rabbit erythrocytes using 
microtiter plate assay 
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Hemagglutination activity of brain iiomogenate 
Sheep {Ovis aries wethers) brain extracts agglutinated, 
trypsinized rabbit erythrocytes. The best solubilizing buffer was found 
to be 75 mM sodium phosphate buffer pH 7.2 containing 150 mM 
sodium chloride, 30 mM lactose and 5 mM 2-mercaptoethanol. 
Lactose was an essential competing saccharide in aqueous buffer for 
efficient solubilization. Moreover, the presence of 2-mercaptoethanol 
was critical during purification procedure, if the reducing agent was 
eliminated from the aqueous buffer, no galectin activity was recovered. 
The galectin activity was unaffected by heat treatment upto 30°C for 
30 min. However, the activity was considerably reduced by the 
addition of high concentration (over 0.5 M) of sodium chloride. The 
galectin mediated hemagglutination of rabbit erythrocytes was inhibited 
by lactose at a concentration as low as 0.4 mM but glucose and 
mannose had no effect even at concentrations of 100 mM. 
Purification of brain galectin 
The purification of brain galectin was based on the procedure 
reported by Avellana-Adalid at al., (1990) with some modifications. 
From the crude sheep brain extracts solubilized in 75 mM sodium 
phosphate buffer, pH 7.2 containing 0.15 M NaCI, 5 mM 2-
mercaptoethanol and 0.02% sodium azide (w/v). Galectin was purified 
by a combination of ammonium sulphate fractionation and affinity 
chromatography. About 3 1 % of the total active protein was 
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precipitated between 30-70% ammonium sulphate saturation resulting 
in a 2.9 fold purification with respect to soluble proteins in the 
homogenate. After extensive dialysis against 75 mM sodium 
phosphate buffer pH 7.2 containing 0.15 M NaCI and 5mM 2-
mercaptoethanol the salt fractionated protein was further 
chromatographed on lactosyl-Sepharose 4B (1.0 x 6 cm) column 
equilibrated with the same buffer. Galectin was readily absorbed on 
the affinity column. No leaching of lectin activity took place during 
washing of the column with the buffer. A 200 mM lactose solution 
proved to be appropriate for the complete elution of the galectin in a 
single symmetrical peak (Fig. 5). The results of purification with 100 
gm sheep brain are shown in Table III. The yield of purified galectin 
was 690 |ig which represented approximately 0.04 percent yield with 
a fold purification of about 1708.3 with respect to soluble proteins in 
the homogenate. The pooled galectin fractions, from the single peak 
of affinity column, migrated as a single protein band in native PAGE 
and SDS - PAGE suggesting homogeneity with respect to charge and 
size respectively (Fig. 6&7). Crude extract and ammonium sulphate 
fractionated sample showed a prominent band of galectin in addition 
to several other bands in both PAGE and SDS-PAGE. 
Properties of purified brain galectin 
Molecular weight 
The molecular weight of sheep brain galectin was determined 
using gel filtration chromatography of sephadex (G-100) column (1.7 x 80 
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FIGURE 5. Purification of the galectin from sheep brain by affinity 
chromatography on lactosyl-Sephorose 4B Column 
About 512 mg of salt fractionated protein, extensively 
dialyzed in 75 mM PBS, pH 7.2 containing 5 mM 2-
mercaptoethanol, was applied to the column ( 1 x 6 cm) 
equilibrated with the same buffer at room temperature. 
The bound protein was eluted at 4°C with 0.2 M lactose 
{i) in 2 ml fractions at a flow rate of 12 ml/hr. The 
protein concentration was determined by the method of 
Bradford (1976). 
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Table -III 
Purification of Sheep brain galectin 
steps of Total Total Specific activity Purification Recovery Yield Volume Titer 
Purification protein Activity (Titer/mg protein) (Fold) (%) (%) (ml) for 
(mg)* (Titer)* 50 nl 
Brain extracT 1617 15200 9,40 1 100 100 190 4 
30-70% ammonium 512 14000 27.34 2.91 92.1 31.7 35 20 
sulphate fractionation 
Affinity chromatography 0.69 11080 16057.97 1708.3 73 0.042 2 277 
Each value represents the mean of three individual experimental observations. 
+ Starting from 100 g fresh tissue. 
# The titer of the tested galectin is experessed as the reciprocal of the highest 
dilution showing agglutination of trypsinized rabbit erythrocytes. 
Determined by the method of Bradford (1976) 
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FIGURE 6. Gel electrophoresis of sheep brain galectin during 
various stages of purification. 
Electrophoresis native was performed on 10% acrylamide 
gel as described under 'materials and methods'. Containing 
the proteins Lane (a) soluble brain extract (25|ig). Lane (b) 
30-70% ammonium sulphate fraction (25ng). Lane (c) the 
fraction of sheep brain galectin (15^g) after affinity 
chromatography on lactosyl-sepherose 4B. 
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FIGURE 7. SDS-PAGE of sheep brain galectin during various 
stages of purification 
Samples were electrophoresed on 12.5% gel under 
reducing conditions as described in the experimental 
section. The gel lanes are as follows: Soluble brain extract 
lane (a), 30-70% ammonium sulphate fraction lane (b) and 
the affinity purified galectin lane (c). 30 ^g protein was 
applied in lanes a and b and 20 \ig protein in lane c. 
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cm) equilibrated with 75 mM PBS pH 7.2. The column was calibrated 
with the marker proteins viz bovine serum albumin (66.2 kDa), ovalbumin 
(45 kDa), soyabean trypsin inhibitor (20.1 kDa) and cytod-irome c (12.4 
kDa) The values of the ratio of elution volume to the void volume i'^J^J 
for each marker protein including sheep brain galectin were calculated as 
shown in the Table IV Analysis of the data indicated a linear relationship 
between Log M and v /^v^ The values of v^v^ for the sheep brain 
galectin under native conditions was found to be 1.83 which 
corresponded to a molecular weight = 28.5 kDa (Fig 8 & Table IV) 
The subunit molecular weight of sheep brain galectin was 
calculated using SDS-PAGE by the procedure of Weber and Osborn 
(1969) Relative mobilities of the marker proteins were plotted against 
the logarithm of molecular weights using least square analysis (Fig. 9). 
The relative mobility of sheep brain galectin in presence and absence of 
reducing agent corresponded to molecular weight of 141 kDa 
Stokes radius 
The stokes radius of sheep brain galectin was determined from 
its elution volume on sephadex G-100 column. The column was 
calibrated by determining the elution volume of several globular 
proteins with known stokes radii The data was analysed according to 
the theoretical treatment of Laurent and Killander (1964) for calculating 
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Table IV 
Various parameters for marker proteins and sheep brain galectin calculated from 
gel filtration chromatography 
Marker proteins Stokes MW 
radius (kDa) 
Log M Elution V^ A/„ (-log Kav)'* 
Volume 
(V) 
Bovine serum 
albumin 
35.5 68 4.82 84 1.40 0.840 
Ovalbumin 27.3 45 4.65 99 1.65 0.701 
Soyabean trypsin 22.6 
inhibitor 
20.1 4.30 120 2.00 0.552 
Cytochrome C 16.4 12.4 4.09 136 2.23 0.449 
Sheep galectin 25.0±1.7 28.5±1.4 4.45 110 1.83 0.619 
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FIGURE 8. Molecular weight estimation of sheep brain galectin 
using Sephadex G-100 gel chromatography. 
Purified sheep brain galectin was applied to a column 
(1.7 X 80 cm) of Sephadex (G -100) under native as well 
as reduced conditions and eluted with 75 mM sodium 
phosphate buffer, pH 7.2 containing 0.15 M NaCI and 5 
mM 2-mercaptoethanol, at a flow rate of 15 ml/hr. The 
molecular weight markers used were bovine serum 
albumin (BSA 68kDa), ovalbumin (OA 45 kDa), 
soyabean trypsin inhibitor (ST 20.1 kDa) and cytochrome 
c (CC 12.4 kDa). The elution position of the lectin 
molecule is indicated with arrow. 
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Figure 9. Estimation of molecular weight of sheep brain 
galectin by SDS - PAGE 
Electrophoresis was carried out according to Laemmli 
(1970) using 12.5% gel. Arrow indicates Rm of Sheep 
galectin. Molecular weight standards were : 1 . 
phosphorylase b (97.4 kDa), 2. bovine senjm albumin (68 
kDa), 3. ovalbumin (45 kDa), 4. carbonic anhydrase (29 
kDa), 5. soyabean trypsin inhibitor (20.1 kDa), 6. 
lysozyme (14.4 kDa). The electrophoretic pattern is shown 
in the inset, purified sheep galectin under reducing and 
non-reducing conditions lanes (a and b) molecular weight 
standards lane (c). 
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Figure 10. Determination of stokes radius of sheep brain 
galectin by Laurent Killander plot. 
The purified sheep galectin and marker proteins were 
subjected to gel filtration on sephadex G-100 column as 
described earlier. The Kav values were computed from 
. the elution volume of marker proteins. Stokes radii for the 
marker proteins were: 35.5A° (bovine serum albumin 
BSA), 27.3 A° (ovalbumin, OA), 22.6 A° (soyabean trypsin 
inhibitor, ST) and 16.4 A° (cytochrome c, CC). The 
Stokes radius of the galectin is indicated by arrow. 
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stokes radiiCA") 
the stokes radius of sheep galectin under native conditions, and 
was found to be 25A° (Fig. 10). 
Carbohydrate binding specificity 
Various members of the galectin family can be distinguished by 
their specificity for saccharides and their derivatives. To confirm and 
compare the galactoside binding specificity of the affinity purified 
sheep brain galectin, hemagglutination inhibition assay was carried out 
using microtiter plate. The inhibitory effect of saccharides on 
agglutination of trypsinized rabbit erythrocytes (4%) by purified brain 
galectin was tested, using a constant hemagglutinating unit of 4. 
Increasing concentration of specific saccharide caused substantial 
deaease in hemagglutination. The most potent inhibitor of sheep brain 
galectin was lactose, giving complete inhibition of hemagglutination at 
a concentration of 0.4 mM followed by galactose (2.5 mM), D-
galactosamine (25 mM), Methyl-p-D-galactopyranoside (50 mM) and p-
nitropenyl-p-D-galactopyranoside (100 mM) as shown in Fig. 11 and 
Table V. Other sugars such as methyl-a-D-galactopyranoside, D-
glucose, p-nitropenyl-a-D-galactopyranoside, D-glucosa^mine, D-
mannose, D-fucose, sucrose, mellibiose, cellobiose, and fructose were 
unable to inhibit the galectin mediated hemagglutination even at a 
concentration of 100 mM. 
66 
Figure 11. Hemagglutination activity inhibition of saccharides. 
Each well contained 50 (il of senally diluted tested sugar, 
50 (il of galectin solution (containing 4 agglutinating unit) 
and 50 |il of 4% suspension of trypsinized rabbit 
erythrocytes. The minimum inhibitory concentration was 
obtained by dividing the starting concentration of the 
carbohydrate which was 200 mM each for A (lactose), B 
(galactose), C (methyl-3-D-galactopyranoside), D (p-
nitrophenyl-p-D-galactopyranoside), E (D-galactosamine) 
by the reciprocal of the highest inhibitory dilution, taking 
into account that due to the addition of galectin, the 
dilution of the test sugar is 1:2 in the first well. 
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Table -V 
Effect of saccharides on the hemagglutinating activity of sheep brain galectin 
Saccharides Minimum concentration of saccharides (mM) 
giving complete hemagglutination inhibition 
Lactose 0.4 
Galactose 2.5 
Methyl -p-D-galactopyranoside 50 
p-nitophenyl-p-D- 100 
galactopyranoside 
D~galactosamine 25 
Methyl-a-D-gaJactopyranoside >100 
p-nitropheny l-a-D-ga lactopyranoside > 100 
D-glucose >100 
D-glucosamine >100 
D-mannose >100 
D-fucose >100 
Suaose >100 
Mellibiose >100 
Cellobiose >100 
Fructose >100 
Each value represents the mean of three independent experiments 
performed in triplicate. 
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Blood group specificity 
The ability of affinity purified sheep brain galectin to agglutinate 
human erythrocytes (Blood groups A,B, AB and 0) and other 
mammalian erythrocytes (sheep, goat and buffalo) was scanned using 
trypsinized as well as untrypsinized preparation of the blood cells. The 
galectin was titrated against erythrocytes showing positive agglutination 
using microtiter plate assay The results are shown in Table VI. The 
concentration of brain galectin required for agglutination varied 
markedly with the type of cell. The rabbit erythrocytes treated with 
trypsin were most sensitive requinng only 1-1.5 iig/ml of galectin to 
agglutinate, while the concentration required for trypsinized human 
erythrocytes was rather high (8-16 |ig/ml). The sheep brain galectin 
did not agglutinate any type of untreated human erythrocytes, but it 
could cause agglutination of trypsinized blood cells, with preference for 
type A erythrocytes rather than 8,0 and AB. Moreover, sheep brain 
galectin did not agglutinate any other native or trypsinized mammalian 
erythrocytes. 
Primary structure analysis 
In order to obtain the amino acid sequence of sheep brain 
galectin, fragments were generated by enzymatic cleavage of the 
purified galectin. Both tryptic and chymotryptic peptides were 
separated by reverse phase HPLC and subsequently submitted to 
amino acid analysis and/or automated sequencing. 
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Table VI 
Mammalian blood specificity of sheep brain galectin 
Blood 
type 
Human 
Sheep 
Goat 
Buffalo 
r 
AB 
lo 
Titer* 
Untrypsinlzed 
-
-
-
-
-
-
Trypsinized 
16 
4 
4 
8 
-
-
-
Titer*: The reciprocal of the highest dilution giving a visible 
hemagglutination. 
4 hemagglutinating units per 50 |il were taken in each assay, the results 
shown are mean of three different preparations taken in triplicate. 
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The HPLC-elution profile of the tryptic peptides is shown in Fig. 
12A. The peaks identified in the figure (designated T1-T9) represent 
pure peptides. Due to incomplete tryptic digestion relatively long 
peptides were obtained. The amino acid sequences of these peptides 
were determined with the exception of T6, which was identified by 
amino acid composition. The presence of the acetyl group in this 
peptide was deduced from its blocked N-terminus and by similarity. 
Fig. 12B shows the HPLC separation of fragments obtained by 
chymotryptic digestion. The amino acid composition of each peptide 
was determined and those presumed to correspond to positions of 
sequence not established by tryptic digestion (C1-C3) were selected 
for Edman degradation. 
The summary of the complete amino acid sequence of the 
sheep brain galectin is given in Fig. 13 and 14, which shows the 
sheep brain galectin-1 sequence alignment with those of human brain 
(Bladier ef a/., 1991), rat brain (Hynes et al., 1988), ovine placenta 
(Iglesias et al, 1998), human placenta (Hirabayashi and Kasai, 
1988), bovine heart (Southan ef al., 1987), rat lung (Clerch et al., 
1988), chicken skin (Ohyama et al., 1986), murine 3T3 fibroblasts 
(Wilson et a/., 1989) and eel electric organ (Paroutaud ef al., 1987), 
showing identities of 92%, 86%, 95%, 91%, 91%, 86%, 59%, 88% 
and 41% respectively. Comparison of the sheep brain galectin 
sequence with the sequences of the other galectins clearly reveales 
that the sheep brain lectin is a member of the galectin family, both in 
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FIGURE 12.HPLC separation of peptides obtained by tryptic (A) 
and chymotryptic (B) digestion of sheep brain 
galectin-1. 
Peptides were separated by reverse phase HPLC on a 
Vydac C^ g column equil ibrated with 0 . 1 % (v/v) 
trifluoroacetic acid in water. Elution was performed at a 
flow rate of 0.8 ml/min with 0-60% acetonitrile linear 
gradient in 0.1% (v/v) trifluoroacetic acid during 100 min. 
The elution was monitored at 220 nm. Peaks T -^Tg and 
C^  - C3 represent peptides whose sequence was 
determined by Edman degradation or inferred from amino 
acid sequence. 
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FIGURE 13.The amino acid sequence of the sheep brain 
galectin. 
The complete sequence for sheep brain galectin is given 
with the residue numbers. 
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Ac 
11 
21 
31 
41 
51 
61 
71 
81 
91 
101 
111 
121 
131 
1 
-Ala 
-Leu 
-Gly 
-Val 
-Leu 
-Ala 
-Asn 
-Glu 
-Pro 
-Phe 
-Pro 
-Arg 
-Ser 
-Val 
2 
-Cys 
-Lys 
-Glu 
-Leu 
-Cys 
-His 
-Ser 
-Gin 
-Gly 
-Asn 
-Asp 
-Leu 
-Ala 
-Ala 
3 
-Gly 
-Pro 
-Val 
-Asn 
-Leu 
-Gly 
-Lys 
-Arg 
-Ser 
-Gin 
-Gly 
-Asn 
-Asp 
-Phe 
4 
-Leu 
-Gly 
-Ala 
-Leu 
-His 
-Asp 
-Asp 
-Ala 
-Val 
-Thr 
-lyr 
-Leu 
-Gly 
-Glu 
5 
-Val 
-Glu 
-Ala 
-Gly 
-Phe 
-Ala 
-Gly 
-Val 
-Ala 
-Asp 
-Glu 
-Glu 
-Asp 
6 
-Ala 
-Cys 
-Asp 
-Lys 
-Asn 
-Asn 
-Gly 
-Ala 
-Glu 
-Leu 
-Phe 
-Ala 
-Phe 
7 
-Ser 
-Leu 
-Ala 
-Asp 
-Pro 
-Thr 
-Ala 
-Phe 
-Val 
-Thr 
-Lys 
-He 
-Lys 
8 
-Asn 
-Arg 
-Lys 
-Ser 
-Arg 
-He 
-Tr]3 
-Pro 
-Cys 
-Val 
-Phe 
-Asn 
-He 
9 
-leu 
-Val 
-Ser 
-Asn 
-Phe 
-Val 
-Gly 
-Phe 
-He 
-Lys 
-Pro 
-T/r 
-Lys 
10 
-Asn 
-Arg 
-Phe 
-Asn 
-Asn 
-Cys 
-Ala 
-Gin 
-Ser 
-Leu 
-Asn 
-Met 
-Cys 
FIGURE 14.Comparison of amino acid sequence of 
representative animal galectins. 
SBG (Sheep brain galectin), present study, nomenclature 
of the peptides is consistent with Fig. 13 HBG, human 
brain galectin (Bladier et a/.,1991); RBG, rat brain 
galectin (Hynes et ai, 1988); ORG, ovine placenta 
galectin (Iglesias et a/.,1998); HPG, human placenta 
galectin (Hirabayashi and Kasai, 1988), BHG, bovine 
heart galectin (Southan et ai, 1987); RLG, rat lung 
galectin (Clerch et ai., 1988); CSL, chicken skin lectin 
(Ohyama et ai, 1986); M3T3, Murine 3T3 fibroblasts 
(Wilson et a/.,1989); and EEL, eel electro lectin 
(Paroutaud et ai, 1987). Identities to the SBG sequence 
are shown at the bottom right. Amino acids from other 
galectins which differ from those present at the same 
position of SBG are indicated in bold, critical amino 
acids which have been shown to be involved in 
interaction with lactose (Lobsanov et ai, 1993) and N-
acetyllactosamine (Liao et ai, 1994; Bourne et ai, 
1994) are also emphasized with "#" (hydrogen bonding) 
or "•" (hydorphobic interaction), and these residues are 
corresponding to the type I CRD invariant amino acids. 
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SBG 
HBG 
RBG 
OPG 
HPG 
BHG 
RLG 
CSL 
M3T3 
EEL 
1 
a C - A C G L V A S N 
10 
L N L K P G E C L 
\ C 2 II C) 
aC- A C G L V AS 
aC- A C G L V AS 
aC- A C G L V AS 
aC- A C G L V A S 
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conserved amino acid sequence and in the absence of other 
domains. Moreover, it is closely related to the galectin-1 subfamily. 
Like other members of this subfamily, the sheep brain galectin-
1 is also a homodimer. It is composed of subunits of 134 amino 
acids, containing only one carbohydrate recognition domain. Besides, 
it shows the characteristics of cytoplasmic proteins, such as an 
acetylated N-terminal amino group and the lack of a hydrophobic 
signal sequence. The sheep brain galectin-1 shows greater identity 
with the ovine placental gaiectin-1 (95%) than with human brain and 
rat brain galectins (92% and 86%) respectively while low identity with 
eel electro lectin (41%), (Fig. 14) was observed. 
Two regions of the galectins seem to have been well conserved 
during evolution. One comprises residues 44 to 55, and the other, 
residues 69 to 83. Common residues in vertebrate galectins are also 
conserved in the sheep brain galectin. These include HIS 44, Asn 46, 
Arg 48, His 52, Asp 54, Asn 61, Trp 68, Glu71 and Arg73, which 
have been shown to be involved in the interaction with carbohydrate 
ligands of galectin either by hydrogen bonding (#) or hydrophobic 
interactions "•" (Fig. 14). 
Free thiol content 
Thiol groups were determined in the purified brain galectin 
using DTNB as described by Ellman (1959). The results (Table VII) 
indicate that sheep brain galectin contains free thiol groups (-SH) at a 
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molar ratio of 1.4, and a total of 6 thiol groups, thus indicating the 
presence of at least six sulphydryl groups per mole of protein. 
Brain ceil agglutination activity 
The results of the brain cell agglutination assays reveal that the 
purified sheep brain galectin has a higher affinity for brain cells of 
sheep rather than goat and buffalo as shown in Fig. 15 and Table 
VIII. The galectin promoted cell aggregation shows involvement of 
multivalent interactions between galectin and brain cell surface 
glycoconjugates. Thus, the galectin showed an affinity for brain cells of 
different mammalian species. 
Effect of thiol blocking reagents on the hemagglutination activity 
of sheep brain galectin 
Sheep brain galectin lost hemagglutinating activity in the 
absence of 2-mercaptoethanol. To examine the role of thiol groups in 
the saccharide bindings, these groups were modified by iodoacetate, 
iodoacetamide, N-ethylmaleimide (NEM) and p-hydroxymenxirybenzoate 
(pHMB). The effect of these alkylating agents on the hemagglutinating 
activity of sheep brain galectin was studied by measuring the time 
course of inactivation by 5mM each of Iodoacetate, iodoacetamide, 
NEM and pHMB in 75 mM sodium phosphate buffer, pH 7.2 
containing 0.15 M NaCI and 1 mM 2-mercaptoethanol. As can be 
seen in Fig. 16, inactivation with pHMB was rather rapid as pHMB is 
substantially more hydrophobic than other alkylating reagents, since it 
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Table Vil 
Thiol group content of sheep brain galectin 
Type of Thiol group Thiol groups/galectin 
(Moles/Mole) 
*Total 
•Free 
6.0 
1.42 
Each value represents the mean of three independent experiments 
performed In triplicate. 
Calculated from amino acid sequence. 
Determined by Ellman method (1959). 
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FIGURE 15. Brain cell aggregation by sheep brain galectin. 
Galectin induced aggregation of brain cells from adult 
sheep (•), goat ( >) and buffalo (o) was detected. The 
rate of decrease in the number of total free particles was 
measured as described under experimental section. 
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Table VIII 
Comparison of brain cell aggregation promoted by purified sheep brain 
gaiectin 
Brain cell 
Tested 
Sheep 
Goat 
Buffalo 
Percent agglutination 
A%* 
85 
77.5 
60 
A% agglutination 
/^g of gaiectin 
A%/ng 
8.5 
7.75 
6.0 
Each value represents the mean of three independent experiments 
performed in triplicate. 
* Percent agglutination represents the percent decrease in particle number 
aftereOmin. at25°C 
79 
inhibited the galectin mediated hemagglutination in less than 25 min. 
However, NEM and iodoacetate led to significant loss (96% & 98%) 
of galectin activity, while iodoacetamide inactivated more than 90% 
activity of sheep galectin within 40 min, but no further significant loss 
of activity was observed. 
Oxidative inactivation of sheep brain galectin 
In order to account for the requirement of reducing agents for the 
maintenance of lectin activity, the time course of inactivation of sheep brain 
galectin was measured by adding 5 mM Hfi^ in 75 mM phosphate buffered 
saline pH 7.2 containing 0.15 M NaCI and 1 mM 2-mercaptoethanol. It can 
be seen that exposure of galectin to Hfi^ caused a significant loss in 
galectin mediated hemagglutination activity (Fig. 17). 
Thermal stability 
The temperature stability of sheep brain galectin was 
determined by the method described in the experimental section. The 
sheep galectin retained full hemagglutination activity when maintained 
at temperature upto 40°C, but gradual decrease was observed 
between 45 to 55°C. A sudden drop of activity occurred when the 
protein was heated at 70°C for 30 min. (Fig. 18). 
pH stability 
The pH dependence of galectin activity was measured at 
various pH values, as described in experimental section. The sheep 
80 
FIGURE 16.Effect of alkylation on hemagglutinating activity of 
sheep brain galectin. 
Hemagglutinating units 256 (80|ig/ml) of sheep galectin 
were incubated at room temperature with 5 mM 
iodoacetate (A) iodoacetamide (o), para-
hydroxymercuribenzoate (•) and N-ethylmaleimide (A) 
respectively for different time intervals (1-60 min.) and 
residual activity was measured by microtiter plate assay 
The "initial activity" refers to hemagglutination activity of 
the unincubated galectin. 
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FIGURE 17. Effect of oxidation on liemagglutinating activity of 
sheep brain gaiectin. 
Hemagglutinating units 256 (80|ig/ml) of sheep gaiectin 
were incubated at room temperature with 5 mM H^Oj for 
different time intervals (1-40 min.) and residual activity 
was measured by microtiter plate assay. The "initial 
activity" refers to hemagglutination activity of the 
unincubated gaiectin. 
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brain galectin showed maximum hemagglutination activity at pH 7.5, 
the galectin was quite stable in the pH range 6.5 to 8.5 (Fig. 19). 
Optical properties 
Ultraviolet (UV) spectra of affinity purified sheep brain galectin 
was measured in 75 mM PBS pH 7.2, containing 5 mM 2-
mercaptoethanol in the wave length 220-350 nm. The results are 
graphically depicted in Fig. 20 The sheep galectin absorbed 
maximally at 280 nm, when the galectin was oxidised in the absence 
of 2-mercaptoethanol by adding 5 mM H^ O^ the absorption peak from 
280 nm was shifted to 250 nm, typical of an oxindole residue, the 
oxidation product of tryptophan. 
Fluorescence Spectra 
The intrinsic fluorescence of protein is contributed by three 
flours- tryptophan, tyrosine and phenylalanine, the excitation at 280 nm 
results in cumulative fluorescence of these aromatic amino acids. 
The fluorescence spectra of native sheep galectin was 
measured in 75 mM phosphate buffered saline containing 5mM 2-
mercaptoethanol in wave length 300-400 nm after excitation at 280 
nm. Exposure of sheep galectin to oxidizing agent (5mM H^Oj) 
resulted in quenching of fluorescence as compared to native galectin. 
However, similar experiment of exposure to H^Oj carried out on brain 
galectin solution containing 0.1 M lactose resulted in slight decrease 
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FIGURE 18. Thermal stability of sheep brain galectin. 
Sheep brain galectin (125 ^g/ml) was incubated at 
different temperatures for 30 min. in 75 mM sodium 
phosphate buffer pH 7 2 containing 0.15 M NaCI and 
5mM 2-mercaptoethanol. The hemagglutinating activity 
was measured by microtiter plate assay. The "initial 
activity" refers to hemagglutination activity of the galectin 
at room temperature of 25°C 
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FIGURE 19.The pH dependence of sheep brain galectin. 
The pH stability of sheep brain galectin (125 ng/ml) was 
determined at various pH (3.5-11.5) taking sodium 
acetate, sodium phosphate, tris-HCI and glycine-NaOH 
buffers as described under experimental section. The 
peak refers to maximum hemagglutinating activity of 
galectin at pH 7.5. 
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FIGURE 20: Ultraviolet spectra of native and oxidized sheep 
galectin. 
Spectra of native sheep brain galectin (150 ng/ml) in 75 
mM sodium phosphate buffer, pH 7.2 containing 0,15 M 
NaCI and 5 mM 2- mercaptoethanol (—) and after adding 
5 mM - HjOj in absence of 2-mercaptoethanol (---). 
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in the fluorescence of the protein-carbohydrate complex. Moreover, the 
presence of lactose in the galectin solution enhanced the fluorescence 
slightly. Thus, it can be concluded that lactose protects the sensitive 
tryptophan residue present in the active site from the oxidizing action 
of H2O2 (Fig. 21). The profile in Fig. 22 depicts the rate of change in 
relative fluorescence at 340 nm. It can be seen that exposure of 
sheep galectin to H2O2 caused a decrease in relative fluorescence 
which took place concomitantly with a deaease in its hemagglutination 
activity as a function of time. 
Circular dichroism 
The far-ultraviolet CD spectra of native sheep brain galectin 
shows low intensity spectrum, with minimum in the 215-217 nm range, 
consistent with the large extent of p-sheet structure profile. Addition of 
lactose produced no significant change in the far-ultraviolet CD 
spectrum (Fig. 23), and the small difference in the spectra obtained in 
the presence and absence of lactose could be attributed to the 
contribution of tryptophan residues to the CD in the far-ultraviolet 
region (Freskgard et al., 1994). These results suggest that there were 
no detectable changes in the secondary structure of SBG upon 
interaction with lactose while exposure of sheep brain galectin to 
oxidizing agent (5mM H^O )^ caused a marked change in the far-
ultraviolet CD spectra with alteration in the p-sheet into a-helix 
structures (Fig. 24). 
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FIGURE 21. Fluorescence spectra of sheep brain galectin. 
Experiments were performed in 75 mM sodium 
phosphate buffer pH 7.2. The spectra of sheep brain 
galectin alone (—) and galectin in presence of 0.1 M 
lactose (—), oxidized galectin (by adding 5 mM H^ O )^ in 
presence of 0.1 M lactose ( ) and oxidized galectin in 
absence of lactose ( ) were measured at 300-
400 nm. Galectin concentration was 100 ng/ml in each 
case. 
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FIGURE 22. The rate of change in relative fluorescence (AF) of 
sheep brain galectin. 
The rate of change in the relative fluorescence of sheep 
galectin at 340 nm on incubation with 4 mM H^O^ was 
measured at 22°C after excitation at 280 nm. 
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The circular-dichroism spectra of sheep brain galectin in the 
near-UV range shown in Fig 25 clearly indicates that the interaction 
of the galectin with lactose did not cause any significant change in 
the near-UV CD spectra of the galectin This indicates that there is no 
change in the tertiary structure upon interaction of the galectin with 
lactose Addition of oxidizing agent (5mM H^O )^ to the galectin 
resulted in subtle changes in the near-uv CD spectra of oxidized 
galectin, indicating a significant change in the tertiary structure of the 
galectin upon oxidation (Fig 26) 
Immunological studies 
Evaluation of antibody response 
The sheep brain galectin was highly immunogenic and readily 
induced antibody formation in rabbits Direct binding ELISA was used to 
charactenze the immune response in rat)bits using pure sheep galectin as 
antigen The antiserum showed a high titer >12,800 (Fig 27) Preimmune 
serum served as negative control and did not show any appreaable binding 
to sheep galectin The galectin preparation also gave a single line of identity 
when tested by the double immunodiffusion method of Ouchterlony (1962) 
(Fig 28) 
Cross-reactivity 
Immunodiffusion studies showed that anti-sheep galectin 
antibodies reacted equally well with both goat and buffalo brain 
galectins, but comparatively a faint precipitin line was observed with 
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FIGURE 23 Far-UV CD spectra of sheep brain galectin. 
The CD spectra obtained in 20 mM PBS pH 7.2, were 
recorded in the absence {—) and presence of 3mM 
lactose (—) in the wave length range of 200-250. 
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FIGURE 24.Far-U\/ CD spectra of sheep brain galectin. 
The CD spectra of native (—) and oxidized (—) sheep 
brain galectin in 20 mM phosphate buffer saline pH 7.2 
were recorded after addition of 5 mM H^ O^ in the wave 
length range of 200-250 nm. 
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FIGURE 25.Near-UV Circular dichroism spectra of sheep brain 
galectin. 
The CD spectra of sheep brain galectin alone (—) and in 
the presence of 3 mM lactose ( ) in 20 mM 
phosphate buffer saline pH 7.2 were recorded in the 
wave length range of 250-300 nm. 
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FIGURE 26.Near-UV Circular dichroism spectra of native and 
oxidized sheep brain galectin. 
The CD spectra of native (—) and oxidized ( ) 
sheep brain galectin in 20mM sodium phosphate buffer 
pH 7.2 after addition of 5 mM H^Oj were recorded in 
the wave length range of 250-300 nm. 
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buffalo brain galectin (Fig. 28) indicating that the antibody was not 
highly specific to buffalo galectin as compared to sheep and goat 
galectins. 
To check possible structural similarity of sheep brain galectin 
with similar lectins present in other organs of sheep, the antiserum 
was tested against various tissue homogenates like heart, liver and 
lung by dot blot analysis. It was found that antibodies reacted strongly 
with all of them (Fig. 29). These results indicated the antigenic 
similarity between both sheep brain galectin and similar lectins from 
other organs of the same species. It would have been interesting to 
check with same organs from goat and baffelo also. 
The specificity of the induced antibodies was confirmed by 
competition ELISA, using purified sheep, goat and buffalo brain 
galectins as competitors. The induced antibodies showed a high 
degree of specificity for sheep galectin (the immunogen). The galectin 
inhibited the antibody binding to the solid phase bound antigen by 
94% (Fig. 30). The concentration of galectin required to achieve 50% 
inhibition was 4 |ig/ml, indicating a high degree of specificity of the 
antibodies. Some degree of crossreactivity was observed with goat 
and buffalo galectins. The percent inhibition of anti-sheep galectin 
antibody activity by goat and buffalo galectins was 86 and 67% 
respectively. The concentration of goat and buffalo galectins required 
to obtain 50% Inhibition was 5 and 10 |ig/ml respectively. On the 
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basis of concentration of inhibitor required for 50% inhibition, the 
percent relative affinities for sheep, goat and buffalo galectins were 
found to be 100%, 80% and 40% respectively (Table IX). The data of 
competition ELISA indicated that the anti-sheep galectin antibodies 
were specific for the immunogen. Nevertheless, it also demonstrated 
cross-reactivity with galectins from different species, indicating that 
these galectins share some common antigenic determinants or 
epitopes. 
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FIGURE 27.ELISA of anti sheep brain galectin. 
Pre-Jmmunized and sheep galectin immunized rabbit sera 
were tested by direct binding ELISA at different dilutions 
(1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 
1:2800). The wells were coated with a solution containing 
2.5 ng/ml sheep brain galectin in 10 mM tris buffer 
saline, pH 7.4. The negative logarithm of serum dilution 
versus the absorbance at 450 nm ( A test - A control) 
for both immunized (0) and preimmunized (•) sera are 
plotted. 
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FIGURE 28.Comparison of the antigenicity of galectin 
preparations from sheep, goat and buffalo brains by 
Ouchterlony immunodiffusion. 
The antigenicity of rabbit antiserum raised against sheep 
brain galectin (well a) was tested against galectins (250 
ng/ml each) from sheep brain, goat brain and buffalo 
brains placed in wells b, c and d respectively 
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FIGURE 29. Dot blot using the anti-sheep galectin anti-serum. 
Tissue homogenates from sheep brain, heart, lung and 
liver were loaded on nitrocellulose membrane sheet which 
was stained with rabbit antiserum raised against sheep 
brain galectin (1: 50 dilution). The spots a, b, c, d and e 
correspond to control (75mM PBS), brain, heart, lung and 
liver tissue homogenates (2 ng) respectively. 
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FIGURE 30.Competition ELISA 
For the antigenic specificity inhibition studies, varying 
amounts (0-20 ng/ml) of inhibitors like purified sheep (0), 
goat ( I) and buffalo (•) brain galectins were taken with 
a constant amount of antiserum (1:100 dilution), raised 
against sheep brain alectin were taken as described 
elsewhere. 
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Table-IX 
Relative binding affinity of anti-sheep brain galectin antibodies to various 
brain galectins 
Inhibitor 
Sheep galectin 
Goat galectin 
Buffalo galectin 
Cone, for 50% 
inhibition 
(liglml) 
4.0 
5.0 
10 
maximum percent 
inhibition 
at 20 ^ g/ml 
94 
86 
67 
Percent 
relative 
affinity 
100 
80 
40 
Each value represents the mean of three independent experiments 
performed in triplicate. 
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(Discussion 
DISCUSSION 
Earlier investigations have revealed the presence of soluble 
carbohydrate binding proteins called lectins which agglutinated 
desialylated rabbit erythrocytes in the brain tissues of various 
mammalian species (Simpson et at., 1977; Kobiler and Barondes, 
1977; Joubert et ai, 1985; Zanetta et ai, 1985; Joubert et ai, 
1986). A growing number of p-galactoside specific lectins have been 
characterized from brains, cerebellum (Kuchler et ai 1989; Caron et 
al., 1990; Gabius and Bardosi, 1990; Zanetta et ai, 1992; Jaison 
and Appukuttan, 1994; Ola et ai, 2001) as well as from other 
tissues like spleen, heart, lung etc. (Barondes, 1984; Harrison et ai, 
1984; Sparrow et ai, 1987; Southan et ai, 1987 Leffler et ai, 
1989; Hirabayashi et a/.,1992). 
The present study demonstrated the presence of a soluble lectin 
capable of agglutinating trypsinized rabbit erythrocytes in the tissue 
extract of sheep brain. This agglutination activity was specifically 
inhibited by lactose. This protein was purified through the procedure 
adopted for human brain galectin (Avellana-Adalid et ai, 1990) with 
slight modification using a combination of ammonium sulphate 
fractionation and affinity chromatography on lactosyl-sepharose 4B 
column. The ammonium sulphate fractionation prior to affinity 
chromatography resulted in a partial purification and enrichment of 
specific activity of the lectin. Affinity chromatography was effective in 
eliminating all of the contaminating proteins and the bound preparation 
was eluted as a single peak using 0.2 M lactose (Fig. 5). This 
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resulted in purification and significant enhancement in the specific 
activity as evident from Table III. The total yield of the purified lectin 
was 0.04%, and was comparable to that reported by others (Bladier 
et al., 1991, Caron et al., 1987, Ola et al., 2001). 
Affinity purified sheep brain lectin moved as a single protein 
band in native PAGE suggesting the homogeneity of the preparation 
(Fig. 6). The brain lectin was also found to be eiectrophoretically 
homogeneous in SDS-PAGE under reducing conditions (Fig. 7). 
Interestingly the subunit molecular weight of the galectin was found to 
be ~ 14.1 kDa (Fig. 9), which is similar to the brain galectins 
isolated from bovine, rat, human and caprine (Caron et al., 1987; 
Avellena-Adalid et al., 1990; Ola et al., 2001). 
The molecular weight of sheep brain galectin under native 
conditions was elucidated using gel filtration chromatography (Fig. 8 
and Table IV) and was found to be 28.5 kDa, while when the sheep 
lectin was electrophoresed in polyacrylamide gel in the presence of 
soaium dodecyl sulphate under reducing as well as non-reducing 
conditions, both preparations showed only monomer of moleculor 
weight of ~ 14.1 kDa (Fig. 9 inset). Thus the sheep brain galectin is 
a dimer of two identical subunits, each of ~ 14 kDa, as was 
reported for other galectins isolated from different mammalian tissues 
includng human, bovine and rat brain galectin (Oda and Kasai, 1983; 
Cerra et al., 1985; Hirabayashi et al., 1987 Caron et al., 1987; 
Bladier et al., 1989), this also implies that it is a homodimeric 
protein with subunits held together by non-covalent interactions. For 
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most galectins, the dimeric form provides the potential to bind to 
glycoconjugates (Drickamer, 1988; Hirabayashi and Kasai, 1993). 
Most galectins bind lactose and N-acelylactosamine (LacNac) 
but there are subtle differences in their carbohydrate specificities 
(Leffler and Barondes, 1986; Oda et al., 1993; Ahmed and Vasta, 
1994). The sugar binding specificity of sheep brain galectin for p-
galactosides resembles that of known brain galectins from bovine, 
rat, goat and human (Leffler and Barondes, 1986; Caron et al. 1987; 
Bladier et al. 1991; Ola et al., 2001). Although it binds to free 
galactose, it has higher affinity for disaccharides, in particular, for 
lactose. The minimum inhibitory concentration required for other 
saccharides was also different, suggesting that the sheep brain 
galectin has its own unique and fine specificity (Sparrow et al., 1987; 
Solis et al., 1996; Kasai and Hirabayashi, 1996). The lactose 
structure is included in a variety of glycoconjugates, such as 
fibronectin, laminin, leukocyte common antigen (CD 45) and 
leukoadhesin (CD43), and has been proposed as the key glycocode 
for galectins (Kasai and Hirabayashi, 1996), 
The results of inhibition studies using a number of saccharides 
shown in Table V and Fig. 11. lead to the conclusion that sheep brain 
galectin is specific for saccharides bearing non-reducing terminal D-
galactose linked in a ^-configuration. This is further supported by the 
observation that the methyl-a-D-galactopyranoside and p-nitrophenyl-a-
D-galactopyranoside are weak inhibitors as compared to methyl-p-D-
galactopyranoside and p-nitrophenyl-p-D-galactopyranoside. However, 
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D-galactose and D-galactosamine were inhibitors which indicate that a 
free hydroxyl, or a free amino group at C-2 is required for mono 
saccharides to cause inhibition. Moreover, the configuration at C-4 is 
also important, since neither glucose nor glucosamine was an 
inhibitor. The fact that lactose is far more inhibitory for 
hemagglutinating activity of the sheep brain galectin suggests that the 
carbohydrate binding site of the galectin could have extended 
geometry which is only partially occupied by galactose molecule. 
As indicated in the table VI, the sheep brain galectin did not 
agglutinate any type of native human erythrocytes, however it 
agglutinated trypsin-treated human blood cells, with a preference for 
type A trypsin treated erythrocytes, rather than 0, B and AB. Thus, it 
is possible that sheep galectin may bind to blood group A 
determinants GalNac instead of Gal and GlcNac (Sparrow et al., 
1987). However, the ability of sheep galectin to agglutinate blood 
group 0 erythrocytes is probably mediated by the 
polylactosaminoglycans found on the human erythrocyte surface 
(Fukuda, 1985). The sheep brain galectin, however, could not 
agglutinate any of the other mammalian erythrocytes (sheep, goat, 
buffalo) possibly due to the absence of glycocodes that are 
recognised by sheep galectin. 
,, The complete amino acid sequence of the 14kDa p-
galactoside-binding protein isolated from sheep brain (Fig. 13,14) is 
clearly similar in sequence to galectin-1 characterized in human, rat, 
ovine, bovine and mouse species. This galectin shows greater identity 
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(95%) with the ovine placental galectin than with the human brain 
galectin (92%) and rat brain galectin (86%). This result is in 
agreement with the suggestion that the 14 kDa galectin-1 is species-
specific rather than organ-specific (Bladier et al., 1991). In addition, 
the high degree of homology between sheep brain galectin and other 
mammalian galectins (86-95%) suggests the high conservation 
throughout evolution, which in turn, shows that they are likely to have 
evolved from common ancestor protein (Hirabayashi et al., 1992). The 
low value of identity with eel electric organ lectin (41%) may be due 
to the phylogenic distance. 
These homologies also suggest that those peptide sequences 
that appear to be highly conserved in all the galectins, would 
correspond to essential structural determinants. For example, the 
tetrapeptide 68-71, which is conserved under the form of W-G-T/A-E 
(Fig. 14), is thought to be part of the saccharide binding site (Levi 
and Teichberg, 1981). 
Moreover, the conservation of amino acid residues that interact 
with the carbohydrate ligands (His 44, Asn 46, Arg 48, His 52, Asp 
54, Asn 61 Trp 68, Glu 70 and Arg 73) suggests the sheep brain 
galectin is having type I (conserved) CRD (Fig. 14). Like other 
members of this subfamily, SBG galectin-1 contains only one CRD 
domain, and hence can be classified as proto-type according to its 
molecular architecture (Hirabayashi and Kasai, 1993). Besides, it 
shows the characteristics of cytoplasmic proteins, such as an 
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acetylated N-terminal amino group and the lack of a hydrophobic 
signal sequence. 
As can be seen in Fig. 14 some of these galectins have a 
possible site of glycosylation: in sheep brain, ovine placenta and 
bovine heart (Asn92- Gln93- Thr94), chicken skin lectin (Asn92-
Pro93- Ser94) and eel (Asn16- Leu17- Thr18) but none of these have 
been reported to be glycosylated. 
Therefore, it can be concluded that there is likely to be one 
gene for the galectin-1 subfamily in sheep as well as in other 
mammals. But this does not exclude the existence of one or more 
other genes coding for more or less related molecules (Gitt and 
Barondes, 1986). Further, the high degree of homology of the 
mammalian galectin-1 subfamily members and their ubiquitous organ 
distribution suggests that they must be involved in some basic 
function. 
Although the exact function of the brain galectin is not known, it 
is interesting to observe that it is a potent inductor of the mammalian 
brain cell aggregation (Fig. 15, Table VIII). It is, important to note that 
galectin - carbohydrate binding need not be the only, or even the 
main, determinant of specificity in brain cell interaction. A requirement 
for dual recognition involving other sets of complementary molecules, 
is consistent with the lectin recognition hypothesis (Caron et al, 1987). 
This result may also imply the involvement of the brain galectins in 
the neuro-transmission process. 
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The number of total thiol groups in the sheep brain galectin as 
determined by amino acid sequence was six moles/mole (Table VII). 
The presence of 1.42 moles/mole of free thiol groups in the galectin 
clearly indicate the presence of intrachain disfulfide bonds as 
observed in rat lung galectin (Whitney et ai, 1986) In order to 
investigate whether free thiol groups were necessary to maintain the 
galectin in its active form, the native sheep brain galectin was 
alkylated by iodoacetate, iodoacetamide, N-ethylmaleimide and p-
hydroxymercuribenzoate respectively This led to a wide range in the 
rates at which the thiol groups were alkylated and resulted in 
inactivation of hemagglutinating activity (Fig. 16). The inactivation of 
hemagglutination activity indicates that the reduced form of cysteine is 
required for the maintenance of the galectin in its active form. The 
loss of galectin activity thus could be due to a possible 
conformational change that occurred during modification of cysteine 
residues (Clerch et ai, 1988), the slow rate of galectin inactivation 
suggests that the functionally relevant cysteine residues could be 
partially buried inside the protein and possibly not involved directly in 
carbohydrate binding but present at a relatively distant site (Whitney 
et ai, 1986). This explains why being most hydrophobic thiol blocking 
reagent, pHMB was most effective to abolish the hemagglutinating 
activity followed by the less hydrophobic NEM and Iodoacetate 
respectively. It is important to note that most galectins are not 
inactivated by iodoacetamide treatment (Hirabayashi et ai, 1987; Ali 
and Salahuddin, 1989), infact some modified galectins showed higher 
108 
activity (Whitney et al., 1986; Clerch et al., 1988). Surprisingly, sheep 
brain galectin was readily inactivated by iodoacetamide. 
In order to account for the requirement of reducing agents for 
the maintenance of activity, the galectin was oxidised by H2O2 (Fig. 
17). This resulted in a significant loss of hemagglutinating activity, the 
oxidative inactivation of sheep brain galectin can be accounted for by 
the formation of intrachain disulfide bond (Whitney et al., 1986), which 
locks the protein into new conformation that cannot form the required 
secondary structure for carbohydrate binding (Clerch et al., 1988). 
The sheep brain galectin was irreversibly inactivated by exposure 
to high temperature during relatively short period of time (Fig. 18), 
similar to other galectins such as bovine spleen galectin (Ahmed et 
al., 1996). 
The pH range for optimal binding activity of the sheep brain 
galectin was rather wide (6.5 - 8.5) (Fig. 19), and overlapped with 
that of its natural physiological environments as reported earlier for 
bovine spleen galectin (Ahmad et al., 1996). 
The ultraviolet absorption studies showed that aromatic 
chromophores in sheep brain galectin include tryptophan residue (Fig. 
20). When sheep brain galectin was oxidized in the absence of 
reducing agent. The uv absorption peak of tryptophan at 280 nm 
shifted to 250 nm. The shift in peak suggests oxidation of tryptophan 
residue to an oxindole moeity which absorbs maximally at 250 nm 
(Levi and Teichberg, 1981). Thus, the reducing agent not only 
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prevents oxidation of cysteine residues in the galectin but also 
protects tryptophan from oxidation. The X-ray studies on bovine spleen 
galectin have shown that Trp-68 is found to make stacking interaction 
with galactose moiety (Abbott and Feizi, 1991; Hirabayashi and Kasai, 
1991; Rini, 1995). Although there is no direct evidence that tryptophan 
is crucial for hemagglutination activity in case of sheep galectin, but it 
may play some role in maintenance of the carbohydrate binding site of 
the galectin molecule. 
The fluorescence spectrum of sheep brain galectin-1 with 
maximum at 330 nm (Fig. 21) is typical of a tryptophan residue in 
hydrophobic environment (Levi and Teichberg, 1981). The exposure of 
sheep brain galectin-1 to oxidation caused quenching in the 
fluorescence which was concomitant with the loss of activity. The 
findings that lactose enhanced the fluorescence of SBG-1 and 
prevented the deleterious effects of oxidizing agent indicated that the 
emitting fluorophore is located within or in the vicinity of the lactose 
binding site and may be readily accessible to lactose (Levi and 
Teichberg, 1981). This suggestion is supported by quenching 
experiments carried out with H^Oj in the presence of disaccharide in 
the galectin solution, which also took place concomitant with the 
finding that Trp 68 is among the highly conserved amino acids and 
involved in binding with lactose by hydrophobic interactions 
(Hirabayashi et ai, 1993; Lobsanov et ai, 1993; Liao et al., 1994). 
The far-uv CD spectrum of native sheep brain galectin (Fig. 23) 
is consistent with the large extent of p-sheet structure as described for 
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other galectins by X-ray crystallography (Liao et al., 1994). Addition of 
lactose (Fig. 23) produced no significant change, thus suggesting that 
the presence of this sugar did not induce any modification on the 
secondary structure of the galectin, while the exposure of the galectin 
to oxidation caused marked change in the CD spectrum with great 
loss in the p-sheet (Fig. 24), which is consistent with the loss of the 
activity upon oxidation that is indicative of a substantial change 
induced in the secondary structure (Yoshimasa et al., 2000).The 
spectral change is also consistent with the disruption of regular 
secondary structure (a-helix and p-sheet) to a random coil. Perhaps 
the intramolecular disulfide bond formation locks the protein into a new, 
inactive conformation that can not form the usual secondary structures 
and can not bind saccharides (Clerch et al., 1988). This suggests 
that the regular secondary stmcture is a vital part of maintaining the 
active galectin conformation. 
The near-uv circular dichroism spectrum shown in Fig. 25 clearly 
shows that the change in the tertiary structure of the protein in the 
presence of lactose is negligible, while the spectra shown in Fig. 26 
may not be the true representation of major conformational changes in 
the protein. The spectra clearly indicated the structural alterations of 
the galectin in the presence of oxidizing agent (HjOj) as compared to 
native sheep brain galectin. This may be due to the change in the 
microenvironment of the aromatic amino acid residues (Creighton, 
1991). 
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In view of the possible cximmon role of brain galectins, it was of 
interest to see whether the isolated galectin is phylogenetically/ 
structurally related to other galectin or is a distinct protein sharing only 
a similar saccharide-binding specificity. Antibodies were raised 
against pure sheep brain galectin in rabbits, the antisera thus 
obtained gave a single precipitin band upon immunodiffusion with the 
antigen i.e. sheep brain galectin. This indicated the homogeneity of 
the preparation. The high titer of the antibody obtained by ELISA (Fig. 
27) suggested that the galectin is highly immunogenic. 
The crossreactivity between sheep, goat and buffalo brain 
galectins was examined by immunodiffusion method (Fig. 28). The 
anti-sheep galectin antibody recognized both goat and buffalo brain 
galectins, but the degrees of cross-reactivity were found to be 
different. The sharing of common antigenic determinants between 
galectins was further studied by competition ELISA (Fig. 30). A high 
degree of inhibition in anti-sheep galectin antibody binding to antigen 
(sheep brain galectin) was observed by galectins from goat and 
buffalo, which were used as inhibitors, however, the extent of binding 
was lower than that observed for sheep galectin. In particular, the goat 
brain galectin seems to show a remarkable structural or 
conformational homogeneity with the sheep brain galectin as it 
inhibited the binding of antibodies to an extent of 86%. The antibodies 
were highly specific for the immunogen, since only 4 ng/ml of sheep 
galectin was required to achieve 50% inhibition, while 5 |ig/ml was 
required in the case of goat galectin to attain 50% inhibition. This is 
112 
also evident from the percent relative affinity of sheep galectin which 
was taken as 100% being the immunogen compared to 80% for goat 
galectin (Table IX) This is, however, expected since both are 
phylogenetically related and would therefore, be expected to have 
common conserved epitopes (Southan et al., 1987; Abbott et al., 
1989; All et al., 1996, Ola et al., 2001). In case of buffalo galectin it 
has shown 67% inhibition with concentration of 10 ng/ml to attain 50% 
inhibition and relative affinity of 40%, compared to goat galectin 
buffalo galectin is a weaker inhibitor, similar results were observed in 
case of anti-goat galectin antibodies (Ola et al., 2001). Thus, the 
competition ELISA data indicated that the galectins from sheep, goat 
and buffalo share common antigenic determinants/epitopes which were 
recognized by the anti-sheep galectin antibodies. The presence of 
cross reacting lectin was detected in the lung, liver and heart tissues 
of sheep by dot blot analysis (Fig. 29). Extensive crossreaction was 
observed for all of them, clearly indicated antigenic cross-reactivity 
between brain galectins of different species, as well as lectins of 
other organs of same species. 
The observations suggested that these galectins may be 
structurally related and may share a common fundamental biological 
role. Thus, the ubiquitous distribution and similarity in structure shows 
that the galectins may be part of independent separate functions 
carried out by the same protein, or they may be part of the same 
functional system. 
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Summary 
SUMMARY 
Galectin is a new family name for a group of animal lectins 
exhibiting specificity for galactosides, known to be widely distributed 
from lower invertebrates to higher vertebrates. Their biological 
significance however, is not yet fully understood because they are 
involved in too many phenomena, such as development, differentiation, 
morphogenesis, metastasis, apoptosis, etc. thus their exact 
physiological functions remain unclear. 
Brain galectin from sheep was purified to homogeneity by the 
combination of 30-70% ammonium sulphate fractionation and affinity 
chromatography on lactosyl-sepharose 4B. The purification resulted in 
1708 fold enrichment of specific activity, with recovery of 73 percent. 
The purified galectin moved essentially as a single polypeptide band 
of 14.1 kDa on SDS-PAGE. The gel filtration behaviour under native 
conditions revealed its molecular weights as 28.5 kDa, with 
corresponding stokes radius of 25A°. No carbohydrate moiety was 
detected in sheep galectin. The most potent saccharide inhibitors 
tested were lactose, D-galactosamine, methyl-p-D-galactopyranoside. 
The galectin preferentially binds to trypsinized human type A 
erythrocycles rather than 0, B and AB while it did not agglutinate 
native or modified erythrocytes of sheep, goat and buffalo. 
The complete amino acid sequence, obtained by tryptic and 
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chymotryptic digestion, revealed that this galectin shares all the 
absolutely preserved and critical residues found in other members of 
the mammalian galectin-1 subfamily it consists of identical single-chain 
polypetide subunits composed of 134 amino acids and its N-terminal 
residue, alanine, is N-acetylated. The sheep galectin preferencially 
agglutinated brain cells from sheep rather than goat and buffalo. 
The galectin strictly requires reducing agent for the maintenance 
of hemagglutination activity. The number of total and free thiol groups 
were found to be 6 and 1.42 respectively. This was further confirmed 
by aikylation of brain galectin by pHMB, NEM, iodoacetate and 
iodoacetamide which resulted in inactivation of hemagglutination 
activity. The exposure of sheep galectin to oxidizing agent (HjOj) 
destroyed its activity, and shifted the uv absorption maxima from 280 
nm to 250 nm, suggesting the oxidation of the single tryptophan 
residue present in the galectin. Conformational changes induced by 
protein interaction with its specific disaccharide as well as oxidizing 
agent (H^Oj) were investigated by intrinsic fluorescence and circular 
dichroism measurements. These two methods indicated changes in the 
environment of aromatic residues upon oxidation, while no significant 
change was observed upon addition of lactose in the far-uv and near-
uv spectra suggesting that it caused no significant modification in the 
secondary as well as tertiary structures of the galectin. Exposure of 
the galectin to oxidizing agent resulted in a drastic change in both its 
secondary and tertiary structures, and also resulted in quenching of 
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the fluorescence intensity which was enhanced by addition of lactose 
to the galectin solution. The sheep galectin was found to have 
maximum hemagglutination activity at pH 7.5 and it was irreversibly 
inactivated by exposure to high temperature above 65°C. 
Antibodies raised against pure sheep brain galectin gave a 
single precipitin band with sheep galectin and the titer determined by 
direct binding ELISA, was found to be more than 12800 suggesting 
that this protein is highly immunogenic. The antibodies also cross-
reacted with purified goat and buffalo brain galectins showing 
antigenic relationship between them. The dot blot experiments 
revealed the presence of other similar lectins in sheep liver, heart and 
lung tissues which cross-reacted with antibodies raised against sheep 
brain galectin. 
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